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ABSTRACT 
According to World Health Organization, cardiovascular diseases are the first cause of 
death worldwide. Although health improved in the last decades, lifestyle changes led to an 
increased incidence of cardiovascular diseases. Currently, the available antithrombotic 
drugs are associated with significant drawbacks that limit their use and the development of 
more advantageous drugs with less secondary effects is necessary. A new class of 
polysulfated small-molecules with anticoagulant and antiplatelet activities was discovered 
in LQOF. However, these polysulfated derivatives showed poor antithrombotic efficacy by 
in vivo oral administration in mice, predicted to be due to poor absorption in the GI tract. 
The main aim of this work was to improve the oral bioavailability of these compounds. In 
order to get new optimized analogues two strategies were considered: i) obtaining 
conjugates with bile acids and ii) introduction of a triazole ring.  
In this dissertation sixteen compounds were synthesized, ten of which were obtained 
and characterized for the first time, including three sulfated derivatives.  
Naringin-deoxycholic acid conjugate 15 was obtained through a crosslinking reaction 
using TBTU as coupling reagent. Triazole linked xanthone glycoside 21 was obtained 
through a copper(I)-catalyzed alkyne-azide cycloaddition following by O- and N-
deacetylation. Sulfation was successfully achieved with triethylamine-sulfur trioxide adduct 
under microwave irradiation. 
Some intermediates (compounds 6, 24, and 26) were tested for cell growth inhibitory 
activity. Rutin peracetate (26) showed good GI50 on six human tumor cell lines in the 
micromolar range. 
The three sulfated derivatives (compounds 16, 22, and 27) were screened for 
anticoagulant activity using the three classic clotting times APTT, PT, and TT. All the 
sulfated compounds prolonged the clotting times, and the most active compound was 
persulfated naringin-deoxycholic acid conjugate 16 exhibiting an APTT2 in the micromolar 
range (44.2 ± 0.2 µM). These new optimized analogues with anticoagulant activity are 
expected to cross the GI tract membranes after oral administration.  
 
 
Keywords: polyphenols; naringin; anticoagulant activity; oral bioavailability 
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RESUMO 
Segundo a Organização Mundial de Saúde as doenças cardiovasculares são a 
principal cause de morte em todo o mundo. Apesar de ter havido um aumento na qualidade 
da saúde nos últimos anos, os hábitos de vida têm-se modificado o que levou ao aumento 
da incidência destas doenças. Atualmente, os fármacos antitrombóticos disponíveis estão 
associados a desvantagens que limitam o seu uso e é necessária a descoberta de 
melhores fármacos com menos efeitos secundários. No LQOF foi descoberta uma nova 
classe de pequenas moléculas polissulfatadas com atividade anticoagulante e 
antiagregante plaquetária. No entanto, estas moléculas demonstraram baixa eficácia 
antitrombótica após administração oral em ratinhos in vivo comportamento associado a 
baixa absorção no trato intestinal. O principal objetivo desta dissertação foi melhorar a 
biodisponibilidade oral desta nova classe de pequenas moléculas polissulfatadas. Duas 
estratégias foram aplicadas no sentido de se atingir o objetivo proposto: i) conjugação com 
ácidos biliares e ii) introdução de um anel triazole. 
Nesta dissertação foram sintetizados dezasseis compostos, dez dos quais foram 
descritos e caraterizados pela primeira vez, incluindo três compostos sulfatados. 
O conjugado naringina-ácido desoxicólico 15 foi obtido através de uma reação de 
ligação cruzada aplicando o TBTU como reagente de acoplamento. A xantona glicosilada 
ligada pelo anel triazole 21 foi obtida através de uma cicloadição alcino-azida catalizada 
por cobre (I), seguida de O- e N-desacetilação. A sulfatação foi realizada em micro-ondas 
utilizando aducto de trióxido de enxofre e trietilamina como reagente de sulfatação. 
Alguns intermediários acetilados (compostos 6, 24 e 26) foram testados pela sua 
inibição do crescimento celular, tendo-se destacado a rutina peracetilada (26) como melhor 
composto, apresentando IG50 na ordem dos micromolar. 
Os compostos sulfatados obtidos (compostos 16, 22 e 27) foram testados in vitro 
quanto à sua atividade anticoagulante através dos testes clássicos de coagulação APTT, 
PT e TT. Os três compostos testados prolongaram o tempo de coagulação e o conjugado 
sulfatado naringina-acido desoxicólico 16 foi o mais ativo, exibindo um APTT2 na ordem 
dos micromolar (44,2 ± 0,2 µM). 
É esperado que os novos análogos otimizados com atividade anticoagulante 
atravessem as membranas no trato gastrointestinal, após administração oral. 
 
Palavras-chave: polifenóis; naringina; atividade anticoagulante; biodisponibilidade oral
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ABBREVIATIONS 
4-NPC - 4-Nitrophenyl chloroformate 
APTT - Activated partial thromboplastin time 
APTT2 – Concentration required to double the activated partial thromboplastin time 
brd - broad duplet 
brs - broad singlet 
d - duplet 
DCC - N,N'-Dicyclohexylcarbodiimide 
dd - double duplet 
DMA - Dimethylacetamide  
DMF - Dimethylformamide 
DMSO - Dimethylsulfoxide 
DOCA - Deoxycholic acid 
DOCA-NH2 - N-Deoxycholylethylamine 
DOCA-NHS - Succinimido deoxycholate 
EDA - Ethylenediamine 
EDAC - 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
EtOH - Ethanol 
FA - Formamide 
FXa - Factor Xa 
GA - 18β-Glycyrrhetinic acid 
GI – Gastrointestinal 
GI50 – concentration required to inhibit growth by 50%. 
HMBC - Heteronuclear multiple bond correlation 
HRMS – High resolution mass spectrometry 
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HSQC - Heteronuclear single quantum correlation 
IR - Infrared 
J - Coupling constant 
LMWH - Low molecular weight heparins 
LQOF – Laboratório de Química Orgânica e Farmacêutica 
m - multiplet 
MCC - Mono-N-carboxymethyl chitosan 
MeOH - Methanol 
MW - Microwave 
NaOAc - Sodium acetate 
NHS - N-Hydroxysuccinimide 
NMR - Nuclear magnetic resonance 
PCP-Cys - Polycarbophil-cystein 
PT - Prothrombin time 
Py - Pyridine 
q - quartet 
s - singlet 
SNAC - Sodium N-(8-(2-hydroxybenzoyl) amino) caprylate 
SNAD - Sodium N-(10-(2-hydroxybenzoyl) amino) decanoate 
SNOCC - N-Sulfonato-N,O-carboxymethylchitosan 
t - triplet 
TBTU - 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoro borate  
THF - Tetrahydrofuran 
TLC - Thin layer chromatography 
TT - Thrombin time 
UFH - Unfractioned heparin  
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OUTLINE OF THE DISSERTATION 
The present dissertation is structured in six chapters: 
INTRODUCTION 
The first chapter includes a brief introduction of oral bioavailability of drugs, a state of 
the art concerning the strategies used to improve oral bioavailability of heparin. The aims 
of this dissertation are presented at the end of this chapter. 
RESULTS AND DISCUSSION 
In this chapter, results obtained from the synthesis, structure elucidation, and biological 
activity will be presented and discussed. 
EXPERIMENTAL SECTION 
In this chapter, the experimental procedures for the synthesis, structure 
characterization, and anticoagulant activity of the synthesized compounds are explained.  
CONCLUSIONS 
This chapter includes the main conclusions of the developed work. 
REFERENCES 
In this chapter, the references cited throughout the thesis are presented. The 
references followed the American Chemical Society style guide. The main bibliographic 
research motors were ISI Web of Knowledge, from Thomson Reuters, Scopus, PubMed 
and Google Scholar. 
APPENDICES 
The last chapter contains folding tables with spectroscopic data of the synthesized 
compounds.
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1.1. Oral bioavailability of drugs 
In the last decades, the focus in the optimization of drug candidates has changed from 
improvement of potency to improvement of drug-like properties. Drug-like properties are 
defined as properties that drug candidates should have to become successful drug 
products.1 Nowadays, drug-like properties are evaluated early, in the drug discovery 
pipeline, in order to eliminate compounds that could fail in clinical trials. 
Oral administration is the most desired administration route and thus oral bioavailability 
plays an important role in drug discovery and development. Poor bioavailability by oral 
administration affects drug’s efficacy and despite other administration routes can be 
chosen, this option should be avoided. 
Several factors affect oral bioavailability of drugs, some being related to chemical 
structure of the drug (e.g. permeability, solubility) and others to the mechanisms developed 
by the organism to get rid of xenobiotics (e.g. first pass metabolism and efflux mechanisms). 
In the gastrointestinal (GI) tract, drugs pass through biological membranes to reach the 
blood circulation using several mechanisms. Passive permeation is the mechanism more 
frequent in drug absorption and is related with solubility properties. Diverse strategies have 
been developed in order to surpass the poor oral absorption of drugs. Among these 
strategies are prodrugs, drug conjugates, structure optimisation and drug formulation. 
Prodrug approach is one of the most successful strategy used to improve oral 
bioavailability of drugs and almost 10% of market drugs are considered prodrugs.2 
International Union of Applied Chemistry defines prodrug as a “drug containing specialized 
nontoxic protective groups used in a transient manner to alter or to eliminate undesirable 
properties in the parent molecule”.3, 4 Prodrugs are inactive compounds that need to be 
bioactivated to have activity. Activation is achieved through modification of the drug´s 
structure. This activation can be enzymatic or chemical before or after absorption. 
Drug conjugates are emerging as a promising strategy to improve oral bioavailability of 
peptides and macromolecules that usually have large molecular weight and fail to be 
absorbed in the GI tract. 5-7 Drug conjugates have also been applied to low molecular weight 
drugs.8, 9 Drug conjugates differ from prodrugs because they retain biological activity. Drugs 
can be conjugated with molecules which: i) will add lipophilic properties to the drug 
improving permeability through lipid membranes or ii) will be recognized by membrane 
transporters allowing the conjugate to cross the membrane through an active mechanism. 
Deoxycholic acid (DOCA) and vitamin B12 have been used to conjugate with both large 
and low molecular weight drugs. DOCA has been conjugated with anticoagulants, antiviral, 
antifungal and antimicrobial drugs.6-9 Vitamin B12 has been conjugated with antidiabetics 
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and anti-obesity drugs.5, 7, 10 Drugs conjugated with these molecules will not pass the GI 
tract membranes through passive mechanisms as there are specific receptors to uptake 
bile acids and vitamins. DOCA is absorbed through apical sodium dependent bile acid 
transporter while vitamin B12 is absorbed by receptor-mediated endocytosis at intrinsic 
factor–B12 receptor in the apical region of enterocytes.11, 12 
Structure optimization involves molecular modifications to improve pharmacokinetic 
properties and to increase the oral availability of drug candidates. There are a set of rules 
that predict if drugs are going to reach blood circulation successfully by passive permeation. 
The most known are the rules of five (Lipinski rules) and three.13, 14 These rules were 
establish through the systematic study of properties of a great number of drugs that use 
passive permeation as the main mechanism to cross biological membranes in the GI tract 
and are widely used to predict oral availability in drug discovery and development. 
Drug formulation regards to the use of excipients or micro and nanoparticles that will 
increase oral absorption of drugs. This strategy is applied mainly for poorly water-soluble 
drugs.  
There are a great number of strategies to improve oral bioavailability of drugs that are 
applied in different stages and having different impacts on drug pharmacokinetic profiles. 
1.2. Strategies to obtain orally-active heparins 
Cardiovascular diseases are the leading cause of deaths in developed countries. New 
oral anticoagulants were recently introduced in the market, namely dabigatran (direct 
thrombin inhibitor), rivaroxaban, and apixaban - factor Xa (FXa) inhibitors -, but there are 
some hesitations about their wide use in the treatment of thromboembolic diseases.15 These 
new anticoagulants seem to be more advantageous than the coumarinic oral 
anticoagulants. Although oraly-active, these drugs lack the polypharmacological actions of 
Heparin or unfractioned heparin (UFH) and low molecular weight heparins (LMWH) which 
are thought to be involved beyond the coagulation cascade16, with antimetastic17 and anti-
inflammatory activities18. 
Heparin has been used in the clinic for more than 80 years and continues to be widely 
used in the treatment of thromboembolic events.19 Heparin (Figure 1) is a mixture of highly 
sulfated glycosaminoglycans with a molecular weight between 5–30 kDa and is one of the 
most negative charged molecules in Nature.20-22 Heparin is an indirect inhibitor of FXa and 
thrombin. LMWH (Figure 1) are also mixtures of glycosaminoglycans but with mean 
molecular weight of about 5 kDa.23 LMWH derive from heparin by chemical or enzymatic 
depolymerization and have a more predictable pharmacokinetic profile.24 
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Figure 1 – Unfractioned heparin (UFH) and low molecular weight heparins (LMWH). 
Compared with warfarin, the most prescribed oral anticoagulant25, heparins have 
several advantages that surpass the fact that they are administered intravenously (Figure 
2).26, 27 
 
Figure 2 - Advantages of heparins over other anticoagulant drugs. 
LMWH can be administered subcutaneously while UFH is administered intravenously, 
23 however none exhibit oral bioavailability due to their highly negative charge, large 
molecular weight,28 and rapid metabolism in the GI tract (Figure 3).29 
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Figure 3 - Structural features of heparins that limit oral bioavailability. 
There have been attempts to find suitable strategies that promote the absorption of 
heparin in the GI tract30 and these can be divided in three main categories: drug conjugates, 
formulation with penetration enhancers, and micro and nanoparticle formulations. 
1.2.1. Drug conjugates 
Following a drug conjugate strategy, heparin has been covalently bond to other 
molecules in order to achieve oral bioavailability in one of two ways: increasing lipophilicity 
and permeability or enabling absorption via transporter proteins or receptor mediated 
endocytosis.31  
There are some small-molecules that have been proven to be suitable choices for 
conjugation with heparin: DOCA and lipids. 
1.2.1.1. Heparin-deoxycholic acid conjugates 
DOCA (Figure 4) is a secondary bile acid produced from cholesterol and one of its 
functions is to stimulate the absorption of lipophilic molecules in the intestine.32 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
5 
 
 
Figure 4 – Deoxycholic acid (DOCA). 
DOCA is absorbed in the intestinal membrane through bile acid transporters and this 
mechanism of absorption would also increase the transcellular absorption of heparin.6 
Studies proved that heparin-DOCA conjugates increased the intestinal absorption of 
heparin, thus increasing its oral bioavailability.6, 33, 34 Anticoagulant activity of heparin is 
conserved in the conjugate. DOCA is a naturally-occurring substance, so its oral 
administration may involve few toxic effects.35 In fact, Lee, et al. carried out histological 
examination of the membrane of the GI tissue after oral administration of heparin-DOCA, 
and no damage to the microvilli and the cell layer was observed.35 
DOCA was conjugated with heparin using several synthetic approaches, although all 
of them involve the formation of an amide bond that will be cleaved after absorption. 
To perform direct conjugation of the carboxylic acid of DOCA with the amine groups of 
heparin, carboxylic acid of DOCA has to be activated (Scheme 1).33, 36 
 
Scheme 1 - Activation of DOCA. NHS - N-hydroxysuccinimide, DCC - N,N-dicyclohexylcarbodiimide; 
THF - tetrahydrofuran; DMF – dimethylformamide. 
After activation, succinimido deoxycholate (DOCA-NHS) reacts instantaneously with 
heparin to form the conjugate (Scheme 2). 
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Scheme 2 - Direct conjugation of heparin and DOCA-NHS. DMF – dimethylformamide. 
Another synthetic approach involves the coupling of the carboxylic acid of heparin and 
the primary amine of N-deoxycholylethylenediamine (DOCA-NH2) previously prepared. 
DOCA-NH2 is obtained through the reaction of DOCA-NHS with ethylenediamine (EDA) 
(Scheme 3). 
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Scheme 3 - Reaction of DOCA-NHS with ethylenodiamine (EDA). DMF - dimethylformamide; r.t. - 
room temperature. 
Activation of the carboxylic acid of heparin is performed before the conjugation reaction 
(Scheme 4). Generally, activating reagents used are 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDAC) alone6, 36-39 or in combination with N-hydroxysuccinimide (NHS)40. 
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Scheme 4 - Activation of the carboxylic acid of heparin. EDAC - 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide; NHS - N-hydroxysuccinimide; FA – formamide; DMF – dimethylformamide. 
Activated heparin and DOCA-NH2 react instantaneously as shown in Scheme 5 to 
originate the heparin-DOCA conjugate. 
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Scheme 5 - Reaction of activated heparin and DOCA-NH2. FA - formamide; DMF - 
dimethylformamide; r.t. - room temperature. 
Conjugation heparin with DOCA through the modification of an aliphatic hydroxyl group 
of DOCA was also described.41, 42 This stratetegy consists in increasing the reactivity of 3-
OH with the introduction of 4-nitrophenyl chloroformate (4-NPC) following reaction 4-
methylmorphline and with EDA as shown in Scheme 6. 
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Scheme 6 - Synthesis of carbamate DOCA. 4-NPC - 4-nitrophenyl chloroformate; NMM – 4-
methylmorpholine; EDA - ethylenediamine. 
Carbamate DOCA further reacts with activated heparin as shown in Scheme 7. 
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Scheme 7 - Conjugation of heparin with carbamate DOCA. 
1.2.1.2. Heparin-fatty acids and heparin-cholesterol conjugates 
Fatty acids are carboxylic acids with a more or less long aliphatic chain, which make 
them amphiphilic compounds. They can be attached to other compounds, making them 
more lipophilic which, in the case of heparin, is useful in the attempt to enhance its 
absorption in the GI tract. 
Lee et al. prepared fatty acids-heparin conjugates with palmitic acid and lauric acid 
(Figure 5).35 The conjugates proved to retain anticoagulant activity and increased the 
absorption of heparin in rats, through the increase of lipophilicity. Palmitic acid and lauric 
acid were coupled with amine groups of heparin through their carboxylic groups. The 
strategy is the same used for heparin-DOCA conjugates.35 
Paliwal et al. also synthesized fatty acids-heparin conjugates, with stearic acid, palmitic 
acid and myristic acid (Figure 5), coupling the carboxylic group of lipids with the amine 
groups of heparin.43 As Lee et al., they proved that these conjugates retained anticoagulant 
activity. 
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Figure 5 – Heparin-fatty acid conjugates. 
Additionally, heparin was conjugated with cholesterol, a sterol that is present and plays 
an essential role in animal cell membranes. Nevertheless, heparin-DOCA conjugates 
showed higher prolonging effects than heparin-cholesterol conjugates.35  
For the heparin–cholesterol conjugate, most of the experimental procedures were 
similar to those with heparin-DOCA. Amide coupling was preceded by the introduction of a 
carboxyl group. This was achieved by alkylation of the hydroxyl group, in which cholesterol 
reacted with chloroacetic acid (Scheme 8).35 
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Scheme 8 - Introduction of a carboxyl moiety in cholesterol. 
In 2000,35 a study showed that heparin-lipid conjugates, such as heparin-cholesterol, 
heparin-palmitic acid, and heparin-lauric acid conjugates had a lower absorption in the GI 
tract, compared with heparin-DOCA conjugate. These findings suggest that DOCA 
increases heparin absorption in the GI tract through receptor-mediated uptake. 
1.2.2. Formulations with penetration enhancers 
Penetration enhancers are compounds used to improve absorption of drugs in the GI 
tract either by opening the tight junctions between adjacent cells, enabling paracellular 
absorption - permeation enhancers - or by increasing the lipophilic properties of the drug 
enabling transcellular absorption - absorption enhancers (Figure 6).31, 44 
 
Figure 6 – Transcellular and paracellular absorption in the GI tract (adapted from 45). 
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The weak association between enhancers and drugs allows the spontaneous release 
of the drug into the circulation.46 However, many of the compounds examined in vitro as 
membrane permeation enhancers cause cytotoxicity or membrane damage. In addition, 
systemic toxic side effects of these compounds cannot be excluded.47 Absorption 
enhancers are low molecular weight compounds that in contrast to permeation enhancers 
do not compromise the integrity of the intestinal epithelium.46 In this section, some 
penetration enhancers that have already been used with heparin and LMWH will be revised. 
1.2.2.1. Permeation enhancers 
 Sodium caprate 
Fatty acids can also be applied as permeation enhancers, enhancing the paracellular 
absorption of hydrophilic drugs at millimolar concentrations. Sodium caprate (Figure 7), the 
sodium salt of the aliphatic saturated 10-carbon fatty acid, capric acid, is the most 
comprehensively characterized medium length fatty acid as permeation enhancer.46, 48 Oral 
delivery of LMWH using sodium caprate as penetration enhancer reached therapeutic levels 
and its cytotoxicity in Caco-2 cells was not found to be severe.49 
 
Figure 7 - Sodium caprate. 
 Glycyrrhetinic acid 
18β-Glycyrrhetinic acid (GA) (Figure 8) is a pentacyclic triterpenoid amyrin derivative 
obtained from the hydrolysis of glycyrrhizic acid, naturally present in the roots of the plant 
Glycyrrhiza glabra. GA was tested as a penetration enhancer in order to increase the 
intestinal absorption of LMWH by Motlekar et al..50 Absorption of a LMWH was increased 
both in vitro and in vivo after co-administration with GA. After exposure to GA, no significant 
toxicity in Caco-2 cells monolayers was found, at relatively low concentrations. The authors 
hypothesised that GA could possibly be used as a penetration enhancer through 
paracellular absorption.51 Although the study was conducted by Hisamitsu Pharmaceutical 
Co., Inc., the company does not seems to be developing a formulation of oral heparin with 
GA at the moment, being GA applied only in transdermal formulations.52 
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Figure 8 - 18β-Glycyrrhetinic acid. 
Recently, anticoagulant properties through uncompetitive inhibition of FXa were 
described for GA.53 
 Mucoadhesive polymers 
Mucoadhesive polymers are polymers that have the capacity to adhere to mucous 
membranes. Chitosan derivatives and thiolated polymers will be addressed in this 
subsection as they increased the absorption of heparin or LMWH in the GI tract.  
Chitosan is a polysaccharide with mucoadhesive properties that comprises 
glucosamine and N-acetylglucosamine subunits.54 In vitro studies have shown that chitosan 
opens epithelial tight junctions in a concentration- and pH-dependent way.54 However, 
chitosan was incompatible with LMWH55 and chitosan derivatives were prepared.56, 57 
Thanou et al. synthesized mono-N-carboxymethyl chitosan (MCC) (Figure 9), a 
polyampholyte chitosan derivative that has shown to increase paracellular absorption of 
LMWH in vitro, in Caco-2 cells monolayers.56 MCC also increased the intestinal absorption 
of LMWH in vivo in rats. When the complex passes the intestinal barrier, it dissociates to 
yield the active macromolecule. 
A sulfonate derivative of N,O-carboxymethyl chitosan (SNOCC) (Figure 9) increased 
the permeation and absorption of LMWH both in vitro in Caco-2 cells monolayer and in vivo 
in rats through intraduodenal administration.57 SNOCC compared with others absorption 
enhancers has the advantage of not being absorbed in the GI tract, which is due to its high 
molecular weight. 
Thiolated polymers or thiomers have improved mucoadhesion properties and 
permeation enhancing properties due to the thiol groups.58 The presence of thiol groups 
offer the advantage to form disulfide bonds between these novel polymers and the mucus 
gel layer, which mimics natural mechanism of secreted mucus glycoproteins, which are also 
covalently anchored in the mucus layer by the formation of disulfide bonds.59 Polycarbophil-
cystein (PCP-Cys) (Figure 9) is a thiomer that was found to increase the absorption of 
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LMWH to anticoagulant levels.58 The oral administration of heparin with PCP–Cys resulted 
in a significantly increased absorption of LMWH compared with control tablets comprising 
unmodified PCP or to an orally given aqueous heparin solution.58 
 
Figure 9 - Mono-N-carboxymethyl chitosan (MCC), a sulfonate derivative of N,O-carboxymethyl 
chitosan (SNOCC), and thiolated polycarbophil (PCP-Cys). 
 SNAC and SNAD 
Sodium N-(8 [2-hydroxybenzoyl] amino) caprylate (SNAD) and sodium N-[10-(2-
hydroxybenzoyl) amino] decanoate) (SNAC) (Figure 10) interact non-covalently with 
heparin, neutralizing its negative ionic charge to render it more lipophilic.44 SNAC  increase 
the absorption of heparin through the GI tract in therapeutic doses.60 Once the complex 
crosses the membrane through a paracellular route, SNAC dissociates from the therapeutic 
agent.46, 61  
 
Figure 10 - Sodium N-(8 [2-hydroxybenzoyl] amino) caprylate (SNAC) and sodium N-[10-(2-
hydroxybenzoyl) amino] decanoate (SNAD). 
Oral heparin/SNAC entered clinical trials and showed good results in healthy volunteers 
and in patients undergoing elective total hip arthroplasty.62 LMWH/SNAD has also shown 
to prevent deep venous thrombosis after oral route.63 These studies demonstrated for the 
first time that heparins can be effectively orally delivered into the bloodstream in patients.64 
However, there are still no formulations with orally-active heparin currently in the 
market.  
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1.2.2.2. Absorption enhancers 
 Polycationic lipophilic-core dendrons 
Polycationic lipophilic-core dendrons (Figure 11) are absorption enhancers that have 
proven to enhance absorption of LMWH in rats. They form lipophilic ion-pairs with the 
polyanionic LMWH making them hydrophobic. This ion-pair model of absorption assumes 
that the dendrons are absorbed as a complex with LMWH.44 However, poor aqueous 
solubility of the complex dendron-LMWH limited its absorption.65 
 
Figure 11 - Polycationic lipophilic-core dendrons. 
 N-Deoxycholylethylenediamine (DOCA-NH2) 
Through lipophilic ion pairing, Lee, et al. designed a DOCA derivative, DOCA-NH2, (see 
Introduction, Scheme 3) to complex with LMWH.66 The complex was dissolved in propylene 
glycol and administered to rats by oral gavage. The physically association of DOCA-NH2 
with LMWH turn the later more lipophilic and in vivo experiments indicated that DOCA-NH2 
significantly affected the oral absorption of the LMWH, and at the molar ratio of 1:5 the oral 
absorption of LMWH was high. Although, the complex LMWH/DOCA-NH2 has reduced 
solubility due to the larger size of the complex and propylene glycol had to be used as 
solubilizer. The oral absorption of LMWH/ DOCA-NH2 complex was higher than those of 
LMWH/DOCA complex. The mechanism used to improve LMWH absorption is not clear and 
may be by bile acids transporters or passive absorption. However, no toxicological studies 
were performed and side effects cannot be excluded. 
The use of penetration enhancers appears to be a good strategy to improve oral 
availability of heparin. An advantage is the preservation of the chemical structure of the 
drug.67 However, toxic effects must be evaluated. Advantages and disadvantages of the 
penetration enhancers presented are illustrated in Table 1. 
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Table 1 - Advantages and disadvantages of penetration enhancers. 
Penetration 
enhancer 
Mechanism Advantages Disadvantages 
Sodium 
caprate* 
Paracellular absorption 
No severe toxicity 
in Caco-2 cells ; 
increase absorption 
at millimolar range 
Local toxicity 
GA* Paracellular absorption 
No significant 
toxicity in Caco-2 
cells monolayers 
after exposure to 
GA 50 
Not described 
Chitosan 
derivatives 
(SNOCC and 
MCC)* 
Increase the residence 
time in the GI tract and 
promote paracellular 
absorption of the drug 
Biocompatible; not 
absorbed (elevated 
molecular weight) - 
few systemic 
side/toxic effects 
Lower efficiency 
of 
MCC when 
compared with 
other delivery 
agents 
Thiomers* Paracellular absorption 
Improved 
mucoadhesion 
properties and 
permeation 
enhancing 
properties due to 
the thiol groups 
Possible toxic 
effects 
SNAC and 
SNAD* 
Paracellular absorption 
Release the drug 
after absorption 
Toxic effects 
(absorbed with 
the drug) 
Polycationic 
lipophilic-core 
dendrons# 
Transcellular 
absorption 
Suitable for 
ionizable molecules 
Absorbed with the 
drug (toxic 
effects); poor 
aqueous solubility 
of the complex 
dendron-LMWH 
DOCA-NH2# 
Transcellular 
absorption 
Recognition 
through bile acid 
transporters 
Not described 
*permeation enhancer; #absorption enhancer. 
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1.2.3. Micro and nanotechnology 
Micro and nanotechnology constitute two approaches widely used in drug delivery to 
enhance drug’s pharmacokinetic profile and decrease its side effects. 
Both polymeric micro and nanoparticles have been used to improve oral absorption of 
heparin.68-72 Biodegradable polymers (poly-ε-caprolactone and poly-D,L-lactic-co-glycolic 
acid) and non-biodegradable polymers (Euparin dragit® RS and RL) were used to prepare 
heparin-loaded nanoparticles.68, 69, 71, 72 It was observed that heparin maintained its 
anticoagulation activity, yet only in vitro studies were performed. These polymers were also 
used to prepare nanoparticles to encapsulate heparin.70 Initial in vitro tests showed 
satisfactory encapsulation efficiency and controlled drug release with retention of the 
anticoagulant activity.72 Further in vivo studies in rabbits showed oral absorption of heparin 
after administration.68 
Later, LMWH (tinzaparin)-loaded nanoparticles were prepared using polyester and 
polycationic polymethacrylate.71 Oral absorption of heparin was improved and its 
anticoagulant effect was prolonged for up to 8 hours. 
It can be found in the literature a combination of strategies through the incorporation of 
lipid-heparin conjugates in solid lipid nanoparticles.43 Incorporation of these conjugates into 
solid lipid nanoparticles significantly improved the bioavailability of LMWH after oral route 
administration with insignificant toxicity to different GI tissue. 
Nevertheless, this approach has drawbacks that are related with the delay they create 
in drug absorption and the lack of control retained over absorption time as a result of the 
variability in intestinal motility and gastric emptying. Toxicity also has to be considered, as 
long as polymeric materials modify tight junctions and could lead to the absorption of 
endotoxins and other potentially toxic compounds.73 
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1.3. Aims: development of polysulfated small-molecules towards new oral 
antithrombotic agents 
In order to discover new antithrombotic drugs with better pharmacokinetic profiles one 
strategy was adopted in Laboratório de Química Orgânica e Farmacêutica (LQOF): 
incorporate an oligosulfated moiety into a phenolic molecule (flavonoid and xanthone) in 
order to mimetize anticoagulant polysaccharides (Figure 12) while increasing the overall 
hydrophobicity.74, 75 In contrast to UFH, polysulfated small-molecules have less charge 
density, reduced anionic character, higher hydrophobic nature, and have a defined 
composition and feasible synthesis. 
 
Figure 12 – Examples of polysulfated glycosidic flavonoids/xanthonoids: rutin persulfate (1), 3,6-(O-
β-glucopyranosyl) xanthone persulfate (2), mangiferin heptasulfate (3) diosmin persulfate (4). 
The anticoagulant activity of these sulfated compounds such as exemplified in Figure 
12 (compounds 1-4) was evaluated in vitro by the classical clotting times. Polysulfated 
compounds 1-4 prolonged activated partial thromboplastin time (APTT)74, 75 and the most 
potent compound (compound 2) exhibited an APPT2 (concentration required to double the 
activated partial thromboplastin time) in the micromolar range (ca 60 µM).75 The 
prothrombin time (PT) or thrombin time (TT) pathways were less affected. After 
intraperitoneal administration in mice, polysulfated compounds revealed a systemic 
anticoagulant action with a rapid onset of action.74, 75 Polysulfated small-molecules showed 
high solubility, stability in human plasma, and efficacy as antithrombotic, and preliminarily 
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in vivo toxicological studies in mice showed that these small-molecules are not expected to 
induce acute hepatic toxicity.74, 75 
Furthermore, some of the synthesized polysulfated derivatives exhibited 
simultaneously anticoagulant and antiplatelet activities.76 Even though a combined 
anticoagulant and antiplatelet therapy for patients with multiple disorders is still discussed, 
compounds combining in the same molecule anticoagulant and antiplatelet activities are 
believed to be promising drugs in preventing and/or treat both venous and arterial 
thrombosis. Dual inhibitors should be advantageous, due to expected less complex 
pharmacokinetics, lower incidence of side effects, and less demanding clinical studies.77 
Nevertheless, after oral administration, none of the tested compounds was active.78 
Thus, the main purpose of this dissertation was the improvement of oral bioavailability 
of these polysulfated small-molecules. 
Two strategies were considered to achieve this purpose: 
i) BILE ACID CONJUGATION 
Conjugation of DOCA was chosen as a potential strategy to improve oral bioavailability 
of polysulfated small-molecules. DOCA is absorbed in the GI tract through specific 
membrane receptors and was successfully used to improve heparin bioavailability without 
significant toxicity (Section 1.2), in contrast to permeation enhancers. In fact, targeting 
membrane receptors is a strategy used for the oral delivery of drugs.31 Fluconazole and 
acyclovir have already been successfully conjugated with molecules that are recognized by 
intestinal receptors to increase oral bioavailability.8, 9 
ii) INTRODUCTION OF A TRIAZOLE 
Introduction of a triazole in the polysulfated glycosidic small-molecules was planned as 
a strategy to increase lipophilicity. Triazole has been used as a strategy to improve 
lipophilicity of several types of drugs,79-81 as antifungal and anti-human immunodeficiency 
virus drugs.80, 81 
Thus, the specific aims were: 
i) to synthesize new phenolic bile acid conjugates, 
ii) to synthesize triazole-linked phenolic glucosides, 
iii) to synthesize sulfated derivatives of the compounds referred in i and ii, 
iv) to characterize through spectroscopic techniques the structure of the 
synthesized derivatives, 
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v) to screen the biological activities of the obtained compounds (i, ii, and iii). 
  
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 - RESULTS AND DISCUSSION 
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2.1. SYNTHESIS 
2.1.1. Conjugation of mangiferin with deoxycholic acid 
Mangiferin (5, Figure 13) is a naturally-occurring xanthone-C-glucoside found mainly 
in mango tree Mangifera indica. Compound 5 was the first xanthone to be investigated 
pharmacologically82 and shows several biological activities, such as antioxidant83-85, 
antidiabetic86, 87, and antiviral.88, 89 Derivatives of compound 5 such as acetyl83, 90, 
propionyl90, 91, butyryl90, cinnamoyl,83 benzyl,92, 93, and substituted anilyl derivatives94-96 also 
displaying a wide range of biological activities were described. 
 
Figure 13 - Mangiferin (5). 
In LQOF, mangiferin heptasulfate (3, Figure 12) was synthesized and in in vitro studies 
showed anticoagulant activity.75 However, in in vivo studies mangiferin heptasulfate (3) was 
not active after oral administration.75 Permeability studies using Ussing chamber verified 
that the compound was not able to cross the intestinal membrane (unpublished results). 
Taking these results in account, conjugation with DOCA was planned in order to 
increase intestinal absorption. 
2.1.1.1. Acetylation of mangiferin (5) 
Compound 5 has four phenolic groups with the following reactivity order: 3, 6, and 7-
OH > 1-OH.97 So, it was planned to protect the phenolic groups of mangiferin except 1-OH, 
to be available for further conjugation with DOCA.  
Acetylation is a commonly used reaction to protect functional groups, because of simple 
deprotection and stability of the groups in mild basic or acid conditions. To obtain the 
acetylated derivative of compound 5 with only 1-OH free, several conditions were attempt 
(Table 2). 
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Table 2 – Tested conditions for acetylation of compound 5. 
Entry Conditions Results 
1 Ac2O, Py, CH2Cl2, r.t.98 
Several partially acetylated products were 
obtained. 
2 
Ac2O/AcOH, NaOAc, 
reflux99 
Several partially acetylated products were 
obtained. 
3 Ac2O, r.t. No product formed 
4 Ac2O, NaF, MW, reflux100 
Several partially acetylated products were 
obtained. 
5 Ac2O, I2, MW, reflux101 Mangiferin peracetate was obtained. 
6 Ac2O, reflux102 
Two principal products were obtained: 
mangiferin hepta- and peracetate 
Ac2O – acetic anhydride; MW – microwave; NaOAc – sodium acetate; Py – pyridine; r.t. – room 
temperature; AcOH – acetic acid. 
Acetic anhydride was the selected reagent to introduce acetyl groups due to its wide 
use in acetylation.21, 101, 103-105 
Since acetylation can be catalysed by bases, acids, metallic and non-metallic Lewis 
acids105-107, pyridine was firstly chosen as the nucleophilic catalyst (Table 2, entry 1). 
Nonetheless, the reaction resulted in several partially acetylated products (Table 2, entry 
1). 
Other bases are employed in acetylation as catalysts, such as NaOAc (sodium 
acetate)∙3H2O.103 Thus, NaOAc∙3H2O in a mixture of acetic anhydride and acetic acid was 
investigated (Table 2, entry 2). These conditions were unsuccessful providing also a 
complex mixture of partially acetylated products. 
NaF, an inorganic salt, was found to be an efficient catalyst in acetylation of hydroxyl 
groups.100 Ready availability and low cost are some advantages of NaF. When applied to 
mangiferin (5) in solvent-free conditions and under microwave (MW) irradiation, several 
partially acetylated products were also obtained (Table 2, entry 4). 
Molecular iodine is described as a strong and efficient catalyst for acetylation of 
alcohols, amines and phenols, being an inexpensive, non-toxic, non-metallic and readily 
available catalyst.108, 109 When iodine was used as catalyst in the acetylation of mangiferin 
(5) in solvent-free conditions using an excess of acetic anhydride under MW irradiation 
(Table 2, entry 5; Scheme 9), this reaction condition gave one major product, mangiferin 
peracetate (6) in 78% yield. 
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Scheme 9 - Synthesis of mangiferin peracetate (6). Ac2O - acetic anhydride; MW - microwave. 
The derivative of compound 5 with the free 1-OH was only obtained after reflux with an 
excess of acetic anhydride (Table 2, entry 6; Scheme 10) in 11% yield.102 Two products 
were obtained and only mangiferin heptaacetate (7) was isolated through flash 
chromatography column. Although the presence was detected by thin layer chromatography 
(TLC) by comparing with a standard, mangiferin peracetate (6) was not isolated. 
 
Scheme 10 - Synthesis of mangiferin heptaacetate (7). Ac2O – acetic anhydride. 
2.1.1.2. Carbomethoxymethylation of mangiferin (5) 
The next synthetic step was the introduction of a carboxylic moiety at 1-position of 
compound 7 to increase reactivity for the following conjugation with DOCA.  
 Several conditions were attempt with compound 7110, 111 but all of them originated a 
complex mixture of compounds. A probably explanation for the formation of a mixture of 
products lies in the fact that acetyl groups may be replaced by alkyl groups.110 Due to this, 
conjugation with DOCA was planned for another compound: naringin. 
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2.1.2. Conjugation of naringin with deoxycholic acid (I) 
Naringin (8, Figure 14) is a flavanone glycoside naturally present in grapefruit and other 
citrus fruits. Similar to other natural flavonoids, compound 8 has a wide variety of biological 
activities and is commercialized as an antioxidant supplement.112-114 Supplementation with 
compound 8 extracted from citrus fruits has been proved to decrease plasma lipid 
concentrations and to improve the antioxidant mechanism system.115, 116 Thus, naringin (8) 
is a suitable model to plan potential antithrombotic derivatives. 
 
Figure 14 – Naringin (8). 
Compound 8 was selected to conjugate with DOCA due to the well-established 
differences in the reactivity of the two phenolic groups present at 5 and 4’ positions: 4’-OH 
is more reactive, while 5-OH is less available due to a hydrogen interaction with the C=O at 
C-4. 
Due to the presence of a single highly reactive phenolic group (4’-OH), direct 
conjugation of compound 8 with DOCA (9) was firstly attempt. 
Esterification of the carboxylic acid of DOCA (9) with the 4’-OH phenolic group of 
compound 8 was investigated using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoro borate (TBTU) as the coupling reagent (Scheme 11). Esterification of carboxylic 
acids with phenols is easily accessible using TBTU in the presence of triethylamine (TEA), 
in smooth conditions and good yields.117  
The coupling reaction is depicted in Scheme 11. Three products were detected but 
only compound 10 was isolated by flash chromatography column following preparative TLC 
in 2.2% yield. Spectroscopic data did not allow to confirm the exactly position of the second 
molecule of DOCA. The other two compounds were hypothesized to be monoconjugates of 
compound 8 with DOCA. 
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Scheme 11 - Synthesis of naringin-di-deoxycholate (10). TBTU - 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoro borate; TEA – triethylamine; THF – tetrahydrofuran; r.t. - room 
temperature. 
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2.1.3. Conjugation of naringin with deoxycholic acid (II) 
2.1.3.1. Carbomethoxymethylation of naringin (8) 
Due to the results obtained in the direct conjugation of naringin (8) with DOCA (9), 
carbomethoxymethylation of 4’-OH was performed in order to increase reactivity in this 
position. 
Methyl 4´-naringin acetate (11) was obtained within 32 hours in 18% yield (Scheme 
12). 
 
Scheme 12 - Synthesis of methyl 4’-naringin acetate (11). DMF - dimethylformamide; r.t. - room 
temperature. 
2.1.3.2. Deacetylation of methyl 4’-naringin acetate (11) 
4’-Naringin acetic acid (12) was obtained using a Zemplén deacetylation123 with sodium 
methoxide in methanol (MeOH) at room temperature (Scheme 13). Zemplén deacetylation 
was selected because of the use of catalytic amounts of base (sodium methoxide), short 
reaction times, and excellent yields.118 
After the completion of the reaction neutralization using an ion exchange column was 
carried out to afford compound 12 in quantitative yields. 
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Scheme 13 - Synthesis of 4’-naringin acetic acid (12). MeONa - sodium methoxide; MeOH - 
methanol; r.t. - room temperature. 
2.1.3.3. Synthesis of succinimido deoxycholate (13) 
Before the conjugation of compound 12 with DOCA (9), activation of compound 9 was 
performed. Succinimido deoxycholate (DOCA-NHS, 13) was synthesized in accordance 
with a method previously reported for the synthesis of heparin-DOCA conjugates (Scheme 
14).39 N,N-Dicyclohexylcarbodiimide (DCC) was used as the coupling reagent. DCC reacts 
firstly with the carboxylic acid of deoxycholic acid and is replaced by NHS to form the 
activated ester DOCA-NHS 13, which is stable and can be isolated. 
 
Scheme 14 - Synthesis of succinimido deoxycholate (DOCA-NHS, 13). NHS - N-
hydroxysuccinimide; DCC - N,N-dicyclohexylcarbodiimide; THF - tetrahydrofuran; r.t. - room 
temperature. 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
32 
 
Purification was accomplished firstly by filtration of the by-product dicyclohexylurea and 
then by precipitation of the product from the reaction mixture. DOCA-NHS (13) was obtained 
in 88% yield. 
2.1.3.4. Synthesis of N-deoxycholylethylenediamine (14) 
The method employed to synthesize N-deoxycholylethylenediamine (DOCA-NH2, 15) 
was previously described in the synthesis of heparin-DOCA conjugates (Scheme 15).6, 36-
39 
 
Scheme 15 - Synthesis of N-deoxycholylethylenediamine (DOCA-NH2, 14). EDA - ethylenediamine; 
DMF - dimethylformamide; r.t. - room temperature. 
The product was obtained with 81% yield in 24 hours after pouring the reaction in ice 
following filtration, which allowed eliminating the unreacted EDA. 
2.1.3.5. Synthesis of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide 
(15) 
A mixture of dimethylformamide (DMF) and H2O is used as solvent in the synthesis of 
heparin-DOCA conjugates.33-35 As heparin is highly soluble in H2O, EDAC, a water-soluble 
coupling reagent, is extensively used for heparin-DOCA conjugation. Compound 12 was 
only soluble in the organic solvent DMF. So, in contrast to heparin methods, we used TBTU 
as the coupling reagent. TBTU was also selected because it was described to allow an 
efficient amidation of carboxylic acids with amines.119 The reaction occurred at room 
temperature with the addition of a catalytic amount of TEA (Scheme 16). 
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Scheme 16 - Synthesis of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide (15). TBTU - 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoro borate; TEA - triethylamine; DMF - 
dimethylformamide; r.t. - room temperature. 
The reaction occurred within 48 hours with 73% yield. After pouring the reaction in ice 
the product was easily isolated by filtration. 
2.1.3.6. Sulfation of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide 
(15) 
Sulfation of compound 15 was accomplished with MW-assisted sulfation using TEA-
sulfur trioxide adduct (SO3:TEA) in dimethylacetamide (DMA) for 2 hours at 100 ºC in 50% 
yield (Scheme 17). 
Sulfur trioxide adducts are successfully applied in the polysulfation and persulfation of 
polyhydroxyl molecules and are mild reagents when comparing with other sulfation 
reagents.120 The use of SO3:TEA was selected due to successful application in the sulfation 
of alcohols in carbohydrate scaffolds and sulfation of phenols.121 MW-assisted sulfation 
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overcomes some limitations of the conventional methods such as long times of reaction and 
the use of high amount of sulfation adduct.122 
 
Scheme 17 - Synthesis of 4’-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide persulfate (16). 
SO3:TEA - triethylamine-sulfur-trioxide adduct; DMA - dimethylacetamide; MW - microwave. 
After the completion of the reaction the TEA salt of the sulfated conjugate was 
converted into the sodium salt with an aqueous solution of NaOAc, followed by 
insolubilization in ethanol (EtOH) to isolate the desirable product 16 in 50% yield. 
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2.1.4. Glycosylation of 3,6-dihydroxy xanthone through a triazole 
2.1.4.1. Copper(I)-catalyzed alkyne-azide cycloaddition 
Among the methods available to form a triazole ring, copper(I)-catalyzed alkyne-azide 
1,4-cycloaddition was selected due to several advantages.123 3,6-bis(1-(2-(2-acetamido-
3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-
yl)methoxy)xanthone (19) was synthesized reacting 3,6-bis(prop-2-yn-yloxy)-9H-xanthen-
9-one (17, previously synthesized in LQOF) with 2-azidoethyl 2-acetamido-3,4,6-tri-O-
acetyl-2-deoxy-β-D-glucopyranoside (18) (Scheme 18). After 30 minutes at 70ºC under MW 
irradiation, compound 19 was easily purified by liquid-liquid extraction and obtained in 73% 
yield. 
 
Scheme 18 - Synthesis of 3,6-bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (19). THF – tetrahydrofuran; MW - 
microwave. 
2.1.4.2. Deacetylation of 3,6-bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-
D-glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (19) 
Deprotection of the glycosidic moiety of compound 19 was achieved under Zemplén 
conditions123 (Scheme 19) in 86% yield. The reaction was complete after 3 hours and 3,6-
bis(1-(2-(2-acetamido-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-
yl)methoxy)xanthone (20) was easily isolated through filtration. Spectroscopic data 
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revealed that the acetyl group of the amide was not removed using these reaction 
conditions. 
 
Scheme 19 - Synthesis of 3,6-bis(1-(2-(2-acetamido-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-
triazole-4-yl)methoxy)xanthone (20). MeONa - sodium methoxide; MeOH - methanol; r.t. - room 
temperature. 
2.1.4.3. N-deacetylation of 3,6-bis(1-(2-(2-acetamido-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (20) 
Hydrolysis of amide bonds is achieved generally using harsh conditions, that is, strong 
acid or base at high temperatures, which could affect other sensitive groups in the 
molecule.124 The presence of electronegative groups in carbon or nitrogen accelerates basic 
catalysis, while alkyl groups in nitrogen retard both basic and acid catalysis.125 
Some synthetic conditions were attempt for deacetylation of O- and N-acetyl groups of 
compound 20. Firstly, a recent method that use mild conditions - Schwartz’ reagent 
(bis(cyclopentadienyl)zirconium(IV) chloride hydride) - was applied, as an alternative to acid 
or base-catalysed hydrolysis.126, 127 However, during the reaction the starting material 20 did 
not react probably because of low solubility. 
A MW-assisted deacetylation method using ammonium salt and EDA was also 
attempt.127 Although this method was successfully applied to a wide range of amides, a 
complex mixture of compounds was obtained. 
N-deacetylation was only achieved using a classic base-catalysed hydrolysis, with an 
aqueous solution of NaOH 20% at 100ºC (Scheme 20) after hydrolysis of the O-acetyl 
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groups using sodium methoxide. Purification was carried out through dialysis following by 
filtration to furnish compound 21 in 36% yield. 
 
Scheme 20 - Synthesis of 3,6-bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-glucopyranosyl)ethyl)-
1H-1,2,3-triazole-4-yl)methoxy)xanthone (21). 
2.1.4.4. Sulfation of 3,6-bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (21) 
Sulfation of compound 21 was achieved under MW irradiation with SO3:TEA in 2 hours 
with 78% yield after isolation by a similar procedure as compound 16 (Scheme 21). 
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Scheme 21 - Synthesis of 3,6-bis(1-(2-(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (22). SO3:TEA - triethylamine-sulfur 
trioxide adduct; DMA - dimethylacetamide; MW - microwave. 
2.1.5. Others 
In the course of this dissertation, to establish future structure-activity relationships with 
the final sulfated products for anticoagulant activity or with acetylated intermediates for 
antitumor activity other phenolic derivatives were obtained and characterized. 
2.1.5.1. Acetylation of diosmin (23) 
Diosmin (23) was acetylated under MW irradiation using NaF as catalyst to give diosmin 
peracetate (24) (Scheme 22). In contrast to mangiferin (5), acetylation of compound 23 
using these reaction conditions lead to the formation of one major product which was 
isolated through crystallization from MeOH/H2O in 63% yield. 
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Scheme 22 - Synthesis of diosmin peracetate (24). Ac2O - acetic anhydride; MW - microwave. 
2.1.5.2. Acetylation of rutin (25) 
Rutin peracetate (26) was obtained through the reaction of rutin (25) with acetic 
anhydride under conventional heating, at 130ºC, with 73% yield (Scheme 23). After 
completion of the reaction the product was isolated through liquid-liquid extraction following 
by insolubilization. 
 
Scheme 23 - Synthesis of rutin peracetate (26). Ac2O - acetic anhydride. 
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2.1.5.3. Sulfation of naringin (8) 
 Naringin persulfate (27) was obtained through the reaction of compound 8 with 
SO3:TEA, under MW irradiation for 1 hour (Scheme 24). 
 
Scheme 24 - Synthesis of naringin persulfate (27). SO3:TEA - triethylamine-sulfur trioxide adduct; 
DMA - dimethylacetamide; MW - microwave. 
Compound 27 was obtained in 48% yield after purification from inorganic salts through 
dialysis. 
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2.2. STRUCTURE ELUCIDATION 
2.2.1. Mangiferin peracetate (6) 
Structure elucidation of mangiferin peracetate (6, Figure 15) was established by 
infrared (IR) and nuclear magnetic resonance (NMR) (1H and 13C) and is in accordance with 
those reported.99, 128 
 
Figure 15 – Mangiferin peracetate (6). 
IR spectrum showed two strong bands at 1754 and 1781 cm-1 typical of C=O ester 
stretching vibration which suggested the presence of acetyl groups (Table 3). 
Table 3 – IR data of compound 6. 
Groups 
(cm-1) 
6 
C-H aliphatic 2937 
C=O ester 1781, 1754 
C=O ketone 1664 
C=C aromatic 1618, 1459 
C-O  1172 
 - wavenumber 
1H and 13C NMR data for compound 6 are presented in APPENDIX I. 
Characteristic signals of the aromatic protons H-4, H-5, and H-8 appeared as singlet at 
δH 7.25, 7.39, and 8.00 ppm, respectively, whereas the corresponding signals of these 
protons appeared at δH 6.38, 6.87, and 7.38 ppm in the non-acetylated parent compound, 
mangiferin (5, also in APPENDIX I). Seven signals characteristic of aliphatic protons (the 
sugar moiety) were observed between δH 3.80-5.73 ppm, whereas the corresponding 
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signals of these protons appeared between δH 3.09-4.59 ppm in the non-acetylated parent 
compound, mangiferin (5). Eight singlets between δH 1.80-2.53 ppm integrating each for 
three protons were assigned for -CH3 protons of acetyl groups, which indicated the 
presence of the peracetylated derivative 6. 
13C NMR spectrum of compound 6 showed eight signals between δC 167.2-170.6 ppm, 
and eight signals between δC 20.3-21.4 ppm, which were assigned to eight C=O of the 
acetyl groups and to eight -CH3 groups, respectively. 
In 13C NMR spectrum of non-acetylated mangiferin (5), carbons C-1, 3, 6, and 7 were 
assigned to δC 161.8, 163.9, 154.1, and 143.8 ppm, respectively, whereas in compound 6 
these carbons were shielded (δC 152.9, 154.4, 152.9, and 139.4 ppm). In contrast, carbons 
C-4 and C-5, in non-acetylated mangiferin (5), were respectively assigned to δC 93.3 and 
102.7 ppm, whereas in compound 6 these carbons were deshielded (δC 111.7 and 112.7 
ppm). 
2.2.2. Mangiferin heptaacetate (7) 
Structure elucidation of mangiferin heptaacetate (7, Figure 16) was established by IR 
and NMR (1H and 13C) and is in accordance with those reported.99 
 
Figure 16 – Mangiferin heptaacetate (7). 
The presence of acetyl groups was suggested by the observation of two strong bands 
at 1779 and 1746 cm-1 typical of C=O ester stretch. Additionally, a large band of stretching 
vibration of the O-H bond at 3443 cm-1 suggested at least one free hydroxyl (Table 4). 
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Table 4 – IR data of compound 7. 
Groups 
(cm-1) 
7 
O-H 3443 
C-H aliphatic 2919, 2850 
C=O ester 1779, 1746 
C=O ketone 1647 
C=C aromatic 1619, 1467 
C-O 1229 
 - wavenumber 
1H and 13C NMR data for compound 7 are also presented in APPENDIX I. 
Characteristic signals of the aromatic protons H-4, H-5, and H-8 appeared as singlets 
at δH 6.76, 7.42, and 8.06 ppm, respectively, whereas the corresponding signals of these 
protons appeared at δH 6.38, 6.87, and 7.38 ppm in the non-acetylated parent compound, 
mangiferin (5, also in APPENDIX I). Seven signals characteristic of aliphatic protons (the 
sugar moiety) were observed between δH 3.81-5.68 ppm, whereas the corresponding 
signals of these protons appeared between δH 3.09-4.59 ppm in the non-acetylated parent 
compound, mangiferin (5). Seven singlets between δH 1.78-2.44 ppm integrating each for 
three protons were assigned for -CH3 protons of acetyl groups, which indicated the 
presence of the peracetylated derivative 7. 
13C NMR spectrum showed seven signals between δC 167.1-170.5 ppm, and seven 
signals between δC 20.4-22.7 ppm, which were assigned to seven C=O of the acetyl groups 
and to seven -CH3 groups, respectively. 
In 13C NMR spectrum of non-acetylated mangiferin (5), carbons C-3, 6, and 7 were 
assigned to δC 163.9, 154.1, and 143.8 ppm, respectively, whereas these carbons were 
shielded (δC 153.9, 148.4, and 139.4 ppm) in compound 7. In contrast, carbons C-4 and C-
5, in non-acetylated mangiferin (5), were respectively assigned to δC 93.3 and 102.7 ppm, 
whereas these carbons were deshielded (δC 110.6 and 112.9 ppm) in compound 7. 
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2.2.3. Naringin-di-deoxycholate (10) 
Structure elucidation of naringin-di-deoxycholate (10, Figure 17) was established by 
IR, NMR (1H and 13C), HSQC, and HMBC. 
 
Figure 17 – Naringin-di-deoxycholate (10). 
IR spectrum showed a band typical of C=O ester stretch at 1737 cm-1 (Table 5). 
Table 5 – IR data of compound 10. 
Groups 
 cm-1 
10 
O-H  3415 
C-H aliphatic 2933, 2865 
C=O ester 1737 
C=O ketone 1642 
C-O 1087 
 - wavenumber 
1H and 13C NMR data for compound 10 are presented in APPENDIX IV. 
1H NMR spectrum showed signals of the flavanone glycoside position and of the steroid 
scaffold. The number of protons indicated the presence of two molecules of compound 9. 
Typical signals of the aromatic protons H-2’, H-6’ and H-3’, H-5’ appeared as duplet at δH 
7.56 and 7.17 ppm, respectively, whereas the corresponding signals of these protons 
appeared at δH 7.33 and 6.80 ppm in naringin (8) indicating that molecular modification 
occurred at 4’-position. Additionally, 1H NMR spectrum showed a singlet at δH 12.03 ppm 
that was assigned for 5-OH. 
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13C NMR spectra showed two signals at δC 173.2 and 172.2 ppm that indicate the 
presence of two carbons typical of C=O ester groups. Carbon C-4’ was assigned to δC 150.7 
ppm, whereas the same carbon was assigned to δC 157.9 ppm in compound 8. 
The assignments of carbon atoms directly bonded to proton atoms were achieved from 
HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 18). 
 
Figure 18 – Main connectivities found in HMBC for compound 10. 
2.2.4. Methyl 4’-naringin acetate (11) 
Structure elucidation of methyl 4’-naringin acetate (11, Figure 19) was established for 
the first time by IR, NMR (1H and 13C), HSQC, and HMBC. 
 
Figure 19 – Methyl 4’-naringin acetate (11). 
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IR spectrum of compound 11 showed a band at 1754 cm-1 characteristic of a C=O ester 
stretch which is in accordance with the molecular modification performed (Table 6). 
Table 6 – IR data of compound 11. 
Groups 
 cm-1 
11 
O-H 3420 
C-H aliphatic 2922 
C=O ester 1754 
C=O ketone 1632 
C=C aromatic 1511 
 - wavenumber 
1H and 13C NMR data of compound 11 is presented in APPENDIX II. 
1H and 13C NMR spectra of compound 11 showed signals that indicate the presence of 
only one carbomethoxymethyl group, namely signals corresponding to the methyl group (δH 
3.71 and δC 51.9 ppm) and to the methylene bridge (δH 4.83 and δC  65.4 ppm). 
Characteristic signals of the aromatic protons H-2’, H-5’, and H-3’, H-6’ appeared at δH 
7.46 and 7.02-6.97 ppm, respectively, whereas the corresponding signals of the same 
protons appeared at δH 7.33 and 6.80 ppm in the parent compound, naringin (8, also in 
APPENDIX II). Signals of the hydroxyl protons of the sugar moiety (δH 4.83-5.15 ppm) and 
the hydroxyl proton at C-5 (δH 12.05 ppm) were also observed in the 1H NMR spectrum of 
compound 11. 
The assignments of carbon atoms directly bonded to proton atoms were achieved from 
HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 20). The position of the 
methylacetate group on naringin was further confirmed by the correlations observed in 
HMBC spectrum between the signal of methylene protons (δH 4.83 ppm) and the signal of 
C-4’ (δC 157.9 ppm) (Figure 20). 
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Figure 20 – Main connectivities found in HMBC for compound 11. 
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2.2.5. 4’-Naringin acetic acid (12) 
Structure elucidation of 4’-naringin acetic acid (12, Figure 21) was established for the 
first time by IR and NMR (1H and 13C). 
 
Figure 21 – 4’-Naringin acetic acid (12). 
IR spectrum of compound 12 showed a band at 1735 cm-1 from the C=O carboxylic 
acid stretch suggesting the presence of the carboxylic acid group (Table 7). 
Table 7 – IR data of compound 12. 
Groups 
 (cm-1) 
12 
O-H 3438 
C-H aliphatic 2919 
C=O carboxylic acid 1735 
C=O ketone 1628 
C=C aromatic 1512 
 - wavenumber 
1H and 13C NMR data for compound 12 are also presented in APPENDIX II. 
1H NMR spectrum showed a signal at δH 13.89 ppm indicating the presence of an acidic 
proton in the carboxylic acid group. When comparing with methyl 4’-naringin acetate (11), 
the 1H NMR and 13C NMR spectra of compound 12 did not show a singlet signal around δH 
3.71 ppm neither a signal corresponding to a -CH3 carbon of an acetate group. 
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2.2.6. Succinimido deoxycholate (13) 
Structure elucidation of DOCA-NHS (13, Figure 22) was established by IR and NMR 
(1H and 13C). The 1H NMR is in accordance with those reported.40 
 
Figure 22 – Succinimido deoxycholate (DOCA-NHS, 13). 
IR spectrum of compound 13 showed bands at 1811, 1781, and 1741 cm-1 typical of 
the C=O stretch vibration (Table 8). 
Table 8 – IR data of compound 13. 
Groups 
(cm-1) 
13 
O-H 3432 
C-H aliphatic 2938, 2863 
C=O (NHS) 1811, 1781 
C=O ester 1741 
 - wavenumber 
1H and 13C NMR data for compound 13 are presented in APPENDIX III. 
1H NMR spectrum showed a multiplet signal integrating for four protons between δH 
2.82-2.87 ppm that was assigned for the aliphatic protons of NHS. 
13C NMR spectrum showed a signal at δC 169.2 ppm that was assigned to the two C=O 
of NHS. Additionally, when comparing with DOCA (9), 1H NMR spectra of compound 13 did 
not show a singlet signal of the acidic proton between δH 12-13 ppm. 
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2.2.7. N-Deoxycholylethylenediamine (14) 
Structure elucidation of DOCA-NH2 (14, Figure 23) was established for the first time by 
IR and NMR (1H and 13C). Although compound 14 is already described in the literature, this 
is the first complete characterization of compound 14. 
 
Figure 23 – N-Deoxycholylethylenediamine (DOCA-NH2, 14). 
The IR spectrum showed two bands at 1558 and 1628 cm-1 of the N-H bend, and a 
band at 671 cm-1 of the N-H wag (Table 9). Overlapping occured in the observed position 
of N-H and O-H stretching frequencies so the presence of a primary amine is difficult to 
confirm. 
Table 9 – IR data of compound 14. 
Groups 
(cm-1) 
14 
O-H/N-H stretch 3600-3200 
C-H aliphatic 2926, 2861 
C=O amide 1694 
N-H bend 1628, 1558 
N-H wag 671 
 - wavenumber 
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1H and 13C NMR data for compound 14 are presented in APPENDIX III. 
1H NMR spectrum showed a triplet integrating for one proton at δH 7.72 ppm typical of 
a secondary amine proton and a quartet integrating for four protons at δH 3.01 ppm that was 
assigned to the methylene protons of the EDA aliphatic chain. 
13C NMR spectrum showed two signals from the carbons of the methylene groups of 
the EDA aliphatic chain (δC 41.4 and 41.6 ppm). 
2.2.8. 4'-Naringin (N-(2-deoxycholan-24-amidoethyl))acetamide (15) 
Structure elucidation of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide (15, 
Figure 24) was established for the first time by IR and NMR (1H and 13C). 
 
Figure 24 – 4’-Naringin (N-(2-deoxycholan-24-amidoethyl))acetamide (15). 
IR spectrum showed bands of the O-H stretch at 3443 cm-1 (Table 10). The band of the 
N-H amide, the C=O ketone stretch, and the C=O amide stretch were overlapped. 
Table 10 – IR data of compound 15. 
Groups 
(cm-1) 
15 
O-H 3443 
C-H aliphatic 2924 
C=O ketone/amide/N-H around 1633 
 - wavenumber 
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1H and 13C NMR data for compound 15 are presented in APPENDIX IV. 
1H NMR spectrum showed singlet signals of two protons of the amide bonds 
between δH 7.79-7.87 ppm and at δH 8.17 ppm which indicate the success of the coupling 
reaction between compound 12 and compound 14. 
13C NMR spectrum showed two signals at at δC 174.3 and 168.6 ppm corresponding 
to the C=O of amide bonds. 
2.2.9. 4’-Naringin (N-(2-deoxycholan-24-amidoethyl))acetamide persulfate (16) 
Structure elucidation of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide 
persulfate (16, Figure 25) was established for the first time by IR, NMR (1H and 13C), HSQC, 
and HMBC. 
 
Figure 25 – 4'-Naringin (N-(2-deoxycholan-24-amidoethyl))acetamide persulfate (16). 
IR spectrum showed bands from the sulfate groups at 1240 cm-1 (S=O), 1058 cm-1 (C-
O-S), and 810 cm-1 (S-O) (Table 11). 
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Table 11 – IR of compound 16. 
Groups 
(cm-1) 
16 
C-H aliphatic 2921, 2863 
C=O ketone/amide 1632 
N-H bend 1558 
S=O 1240 
C-O-S 1058 
S-O 810 
 - wavenumber 
1H and 13C NMR data for compound 16 is presented in APPENDIX IV. 
1H NMR spectrum of compound 16 did not show signals in the typical region of hydroxyl 
proton signals (δH 4.53-5.36 ppm) when compared to compound 15. Twelve signals 
characteristic of aliphatic protons (the sugar moiety) were observed between δH 3.70-4.75 
ppm in compound 16, whereas the corresponding signals of these protons appeared 
between δH 3.35-3.77 ppm in the non-sulfated parent compound, 4'-naringin (N-(2-
deoxycholan-24-amidoethyl))acetamide (15, also in APPENDIX IV). Signals of H-3 and H-
12 of the steroid moiety appeared at δH 3.70-4.01 and 4.42-4.53 ppm, respectively, whereas 
the corresponding signals of these protons appeared at δH 3.70-4.01 and 4.42-4.53 ppm in 
the non-sulfated parent compound, 4'-naringin (N-(2-deoxycholan-24-
amidoethyl))acetamide (15). 
13C NMR spectrum showed signals of the C=O group of the amide bond at δC 173.1 
and 167.8 ppm. Signals of the ethyl linker between the amide bonds were observed at δC 
38.4 and 38.2 ppm, and of the 4’-OCH2 at δC 67.0 ppm. 
The assignments of the carbon atoms directly bonded to proton atoms were achieved 
from HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 26). 
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Figure 26 - Main connectivities found in HMBC for compound 16. 
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2.2.10. 3,6-Bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (19) 
Structure elucidation of 3,6-bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (19, Figure 27) was 
established for the first time by IR, NMR (1H and 13C), HSQC and HMBC. 
 
Figure 27 – 3,6-bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-
1,2,3-triazole-4-yl)methoxy)xanthone (19). 
IR spectrum showed one band at 1745 cm-1 of C=O ester stretch (Table 12) and also 
a band at 2957 cm-1 of C-H stretch that suggest the presence of a sugar moiety. 
Table 12 – IR data of compound 19. 
Groups 
(cm-1) 
19 
C-H aliphatic 2957 
C=O ester 1745 
C=O ketone/amide 1660 
N-H bend 1609 
 - wavenumber 
1H and 13C NMR data for compound 19 are presented in APPENDIX V. 
The success of the molecular modification performed was confirmed by 1H NMR and 
13C NMR that showed signals of the triazole ring (δC 125.4 ppm, δH 8.15 ppm, and δC 141.5 
ppm of CH=C, respectively) and of the sugar moiety (δH 1.71-2.02 ppm and δC 20.2-22.6 
ppm of the -CH3 groups, and δC 169.1-170.1 ppm of the C=O of the acetyl groups). 
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Assignments of the carbon atoms directly bonded to proton atoms were achieved from 
HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 28). 
 
Figure 28 – Main connectivities found in HMBC for compound 19. 
2.2.11. 3,6-Bis(1-(2-(2-acetamido-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-
triazole-4-yl)methoxy)xanthone (20) 
Structure elucidation of 3,6-bis(1-(2-(2-acetamido-2-deoxy-β-D-glucopyranosyl)ethyl)-
1H-1,2,3-triazole-4-yl)methoxy)xanthone (20, Figure 29) was established for the first time 
by IR, NMR (1H and 13C), HSQC and HMBC. 
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Figure 29 - 3,6-Bis(1-(2-(2-acetamido-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-
yl)methoxy)xanthone (20). 
IR spectrum of compound 20 did only present a band at 1648 cm-1 typical of the C=O 
ketone stretch which suggest that acetyl groups were removed (Table 13). 
Table 13 – IR data of compound 20. 
Groups 
(cm-1) 
20 
O-H 3415 
C-H aliphatic 2919 
C=O ketone/amide 1648 
N-H bend 1610 
 - wavenumber 
1H and 13C NMR data for compound 20 are presented in APPENDIX V. 
1H NMR spectrum showed signals between δH 4.57-5.08 ppm which is in accordance 
with the presence of hydroxyl protons. 
In 13C NMR spectrum of compound 19, carbons C-1’, C-3’, and C-4’ were assigned to 
δC 99.8, 68.4, and 70.7 ppm, respectively, whereas these carbons were deshielded (δC 
100.7, 70.5, and 74.1 ppm) in compound 20. 
The assignments of the carbon atoms directly bonded to proton atoms were achieved 
from HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 30). 
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Figure 30 – Main connectivities found in HMBC for compound 20. 
2.2.12. 3,6-Bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-glucopyranosyl)ethyl)-
1H-1,2,3-triazole-4-yl)methoxy)xanthone (21) 
Structure elucidation of 3,6-bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (21, Figure 31) was 
established for the first time by IR, NMR (1H and 13C). 
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Figure 31 – 3,6-Bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-
triazole-4-yl)methoxy)xanthone (21). 
The IR spectrum showed bands of N-H bend and of N-H wag at 1609 and 841 cm-1, 
respectively (Table 15). Overlapping occured in the observed position of N-H and O-H 
stretching frequencies so the presence of a primary amine is difficult to confirm. 
Table 14 – IR data of compound 21. 
Groups 
(cm-1) 
21 
O-H 3362 
C-H aliphatic 2920, 2880 
C=O ketone/amide 1641 
N-H bend 1609 
N-H wag 841 
 - wavenumber 
1H and 13C NMR data for compound 21 are presented in APPENDIX V. 
Comparing with the starting material, compound 20, the 1H NMR spectrum of 
compound 21 did not show the signal in the typical region of the -CH3 protons of the 
acetamide group (-NHCOCH3). A singlet signal of two protons at δH 1.44 ppm was observed 
which indicate the presence of a primary amine. 
2.2.13. 3,6-Bis(1-(2-(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (22) 
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Structure elucidation of 3,6-bis(1-(2-(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (22, Figure 32) was 
established for the first time by IR, NMR (1H and 13C), HSQC, and HMBC. 
 
Figure 32 – 3,6-Bis(1-(2-(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-
triazole-4-yl)methoxy)xanthone (22). 
IR spectrum showed bands at 1257 cm-1 (C-O-S), 1047 cm-1 (S=O), and 814 cm-1 (S-
O) (Table 15) which suggests the presence of sulfate groups. 
Table 15 - IR data of compound 22. 
Groups 
(cm-1) 
22 
C-H aliphatic 2917, 2847 
C=O ketone/amide 1642 
N-H bend 1619 
C=O 1257 
C-O-S 1047 
S-O 814 
 - wavenumber 
1H and 13C NMR of compound 22 are presented in APPENDIX V. 
When comparing with the starting material, compound 21, signals of hydroxyl protons 
were not observed in the 1H NMR spectrum of compound 22. 1H NMR spectrum also 
showed a signal at δH 1.73 ppm integrated for two protons which indicate that the amine 
group was not modified. 
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In 13C NMR spectrum of compound 21, carbons C-1’, C-3’, C-4’, and C-6’ were 
assigned to δC 101.5, 70.9, 76.5, and 61.1 ppm, respectively, whereas these carbons were 
shielded (δC 100.5, 70.5, 74.5, and 60.9 ppm), in compound 22. 
The assignments of the carbon atoms directly bonded to proton atoms were achieved 
from HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 33). 
 
Figure 33 - Main connectivities found in HMBC for compound 22. 
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2.2.14. Diosmin peracetate (24) 
Structure elucidation of diosmin peracetate (24, Figure 34) was established by IR and 
NMR (1H and 13C). The 1H NMR is in accordance with those reported.129 
 
Figure 34 – Diosmin peracetate (24). 
The IR spectrum showed a band at 1754 cm-1 (C=O ester stretch) that suggests the 
presence of acetyl groups (Table 16). 
Table 16 – IR data of compound 24. 
Groups 
(cm-1) 
24 
C-H aliphatic 2940 
C=O ester 1754 
C=O ketone 1644 
C=C aromatic 1614, 1514, 1433 
C-O 1289 
C-H aromatic 982 
 - wavenumber 
1H and 13C NMR data of compound 24 are presented in APPENDIX VI. 
Characteristic signals of the aromatic protons H-2’, H-5’, and H-6’ appeared at δH 7.56, 
7.08, and 7.72 ppm, respectively, whereas the corresponding signals of these protons 
appeared at δH 7.41, 7.10, and 7.54 ppm in the non-acetylated parent compound, diosmin 
(23, also in APPENDIX VI). Twelve signals characteristic of aliphatic protons (the sugar 
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moiety) were observed between δH 3.65-5.98 ppm, whereas the corresponding signals of 
these protons appeared between δH 3.13-5.03 ppm in the non-acetylated parent compound, 
diosmin (23). Eight singlets between δH 1.92-2.43 ppm integrating each for three protons 
were assigned for -CH3 protons of acetyl groups, which revealed the formation of the 
peracetylated derivative 23. 
13C NMR spectrum showed eight signals between δC 168.8-170.2 ppm, and eight 
signals between δC 20.6-31.0 ppm, which were assigned to eight C=O of the acetyl groups 
and to eight -CH3 groups, respectively. 
In 13C NMR spectrum of non-acetylated diosmin (23), carbons C-5 and 3’ were 
assigned to δC 161.1 and 146.9 ppm, respectively, whereas these carbons were shielded 
(δC 159.8 and 140.1 ppm) in compound 24. In contrast, carbons C-3 and C-8, in non-
acetylated diosmin (23), were respectively assigned to δC 105.7 and 95.1 ppm, whereas 
these carbons were deshielded (δC 109.0 and 97.8 ppm) in compound 24. 
2.2.15. Rutin peracetate (26) 
Structure elucidation of rutin peracetate (26, Figure 35) was established by IR, NMR 
(1H and 13C), HSQC and HMBC. The NMR (1H and 13C) is in accordance with those 
reported.129, 130 
 
Figure 35 – Rutin peracetate (26). 
IR spectrum showed two bands at 1754 and 1781 cm-1 (C=O ester stretch) suggesting 
the presence of acetyl groups (Table 17). 
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Table 17 – IR data of compound 26. 
Groups 
(cm-1) 
26 
C-H aliphatic 2940 
C=O ester 1781, 1754 
C=O ketone 1628 
C=C aromatic 1505, 1477, 1435 
C-O 1145 
 - wavenumber 
1H and 13C NMR data for compound 26 are presented in APPENDIX VII. 
Characteristic signals of the aromatic protons H-2’, H-5’, and H-6’ appeared at δH 7.91, 
7.34, and 7.96 ppm, respectively, whereas the corresponding signals of these protons 
appeared at δH 7.54, 6.85, and 7.56 ppm in the non-acetylated parent compound, rutin (25, 
also in APPENDIX VII). Twelve signals characteristic of aliphatic protons (the sugar moiety) 
were observed between δH 3.26-5.43 ppm, whereas the corresponding signals of these 
protons appeared between δH 3.06-5.37 ppm in the non-acetylated parent compound, rutin 
(25). Ten singlets between δH 1.60-2.44 ppm integrating each for three protons were 
assigned for -CH3 protons of acetyl groups, which revealed the formation of the 
peracetylated derivative 26. 
13C NMR spectrum showed eight signals between δC 167.8-170.2 ppm, and eight 
signals between δC 20.6-21.2 ppm, which were assigned to seven C=O of the acetyl groups 
and to seven -CH3 groups, respectively. 
In 13C NMR spectrum of non-acetylated rutin (25), carbons C-5, 7, 3’, and 4’ were 
assigned to δC 161.3, 164.1, 144.8, and 149.5 ppm, respectively, whereas these carbons 
were shielded (δC 150.2, 153.9, 141.8, and 144.1 ppm) in compound 26, In contrast, 
carbons C-6 and C-8, in non-acetylated rutin (25), were respectively assigned to δC 98.8 
and 100.8 ppm, whereas these carbons were deshielded (δC 113.4 and 109.1 ppm) in 
compound 26. 
The assignments of the carbon atoms directly bonded to proton atoms were achieved 
from HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 36). 
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Figure 36 - Main connectivities found in HMBC for compound 26. 
2.2.16. Naringin persulfate (27) 
Structure elucidation of naringin persulfate (27, Figure 37) was established for the first 
time by IR, NMR (1H and 13C), HSQC, HMBC, and high resolution mass spectrometry 
(HRMS). 
 
Figure 37 – Naringin persulfate (27). 
IR spectrum showed bands at 1254 cm-1 (S=O), 1052 cm-1 (C-O-S), and 810 cm-1 (S-
O) suggesting the presence of sulfate groups (Table 18). 
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Table 18 – IR data of compound 27. 
Groups 
 (cm-1) 
27 
C=O ketone 1637 
C=C aromatic 1518 
S=O 1254 
C-O-S 1052 
S-O 810 
 - wavenumber 
1H and 13C NMR data for compound 27 are presented in APPENDIX II. 
Characteristic signals of the aromatic protons H-2’, H-5’ and H-3’, H-6’ appeared as 
duplets at δH 7.58 and 7.17 ppm, respectively, whereas the corresponding signals of these 
protons appeared at δH 7.33, and 6.80 ppm in the non-sulfated parent compound, naringin 
(8, also in APPENDIX II). Twelve signals characteristic of aliphatic protons (the sugar 
moiety) were observed between δH 3.71-5.31 ppm, whereas the corresponding signals of 
these protons appeared between δH 3.15-5.14 ppm in the non-sulfated parent compound, 
naringin (8). 
In 13C NMR spectrum of non-sulfated naringin (8), carbons C-5 and C-4’ were assigned 
to δC 162.9 and 157.9 ppm, respectively, whereas these carbons were shielded (δC 157.0 
and 155.6 ppm) in compound 27. In contrast, carbons C-6 and C-8, in non-sulfated naringin 
(8), were respectively assigned to δC 96.3 and 95.2 ppm, whereas these carbons were 
deshielded (δC 97.1 and 96.0 ppm) in compound 27. 
The assignments of the carbon atoms directly bonded to proton atoms were achieved 
from HSQC experiments and the chemical shifts of the carbon atoms not directly bonded to 
proton atoms were deduced from HMBC correlations (Figure 38). 
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Figure 38 - Main connectivities found in HMBC for compound 27. 
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2.3. BIOLOGICAL ACTIVITIES 
2.3.1. Antitumor activity 
Flavonoids and xanthones are privileged structures, what explains the wide range of 
biological activities that they display. Natural products such as xanthones and flavonoids 
are well known for their antitumor properties.82, 131  
Acetylated derivatives possessing antitumor activity have been described in the 
literature.132-135 
Mangiferin heptaacetate (6), diosmin peracetate (26) and rutin peracetate (27) were 
evaluated in vitro for growth-inhibitory effect on three human tumor cell lines: A375-C5 
(malignant melanoma IL-1 insensitive), MCF-7 (breast adenocarcinoma), and NCI-H460 
(bronchioalveolar carcinoma) using a sulforhodamine B assay (Table 19), a methodology 
that determines cell density, based on the measurement of cellular protein content. These 
studies were performed at CESPU by Patrícia Duarte and Patrícia Silva under supervision 
of Professor Hassan Bousbaa. 
A pronounced growth-inhibitory effect was observed for compounds 6 and 26 against 
the three human tumor cell lines (Table 19). Compound 26 was more potent than compound 
6 in all the three cell-lines. 
Table 19 – Cell growth inhibition activity displayed by compounds 6, 24, and 26 on three human 
tumor cell lines. 
Compounds 
GI50(μM) 
A375-C5 MCF-7 NCI-H460 
6 56.12 ± 1.69 87.98 ± 2.73 95.79 ± 5.65 
24 >150 >150 >150 
26 8.29 ± 2.98 18.98 ± 5.12 17.57 ± 2.46 
Doxorrubicin was used as positive control. GI50 - concentration for 50% of maximal inhibition of cell 
proliferation. 
Compounds 6 and 26, the most promising compounds, were further tested against 
three human tumor lines of glioblastoma. Compound 26 was also shown to have potent 
inhibitory effect on the human glioblastoma cell lines tested (Table 20). 
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Table 20 – Cell growth inhibition activity of compounds 6 and 26 on three human glioblastoma cell 
lines. 
Compounds 
GI50(μM) 
U251 U373 U87MG 
6 >150 >150 >150 
26 21.57 ± 3.03 18.77 ± 2.01 13.13 ± 0.68 
Doxorrubicin was used as positive control. GI50 - concentration for 50% of maximal inhibition of cell 
proliferation. 
Compound 26 was the only compound that showed potent inhibitory effects against all 
the human tumor cell lines tested. These results stimulate the future synthesis of other 
polyphenolic compounds to establish other structure-activity relationships. Although the 
number of derivatives investigated was very reduced, it is possible to infer that the position 
of the sugar moiety seems to be critical for the inhibitory activity. 
2.3.2. Anticoagulant activity 
4'-Naringin (N-(2-deoxycholan-24-amidoethyl))acetamide persulfate (16), 3,6-bis(1-(2-
(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-
yl)methoxy)xanthone (22), and naringin persulfate (27) were screened in vitro for 
anticoagulant activity by the three classical coagulation times: APTT, PT, and TT (Figure 
39). These clotting assays are commonly used in clinical laboratory for monitoring 
anticoagulant drugs in patients and in research laboratories to test anticoagulant activity of 
new compounds. 
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Figure 39 - Representation of the coagulation cascade and the classical clotting assays. 
APTT is one of the most used clotting assays and measures the activity of a large 
number of factors of the intrinsic and common pathways of the coagulation (Figure 39). 
This assay is performed using plasma previously treated with sodium citrate to prevent 
coagulation. A negative charged activator is added to the citrated plasma and addition of 
calcium initiates the coagulation process. The APPT is measured after the activation of 
factor XII until the formation of a stable clot. 
PT is widely used in health care to diagnose the risk of bleeding and to monitor oral 
anticoagulation therapy.136 The PT test specifically measures the activity of coagulation 
factors of the extrinsic and common pathway (Figure 39). The test involves re-calcification 
of plasma once the sample has been incubated with the tissue factor source (apoprotein 
and phospholipid). The PT is measured after the activation of FXa until the formation of a 
stable clot. 
TT measures the time required for formation of a stable clot, following addition of 
thrombin to citrated plasma.137 The TT test is commonly used to diagnose deficiencies in 
fibrinogen (Figure 39) and measures the time since the addition of thrombin until the 
formation of a stable clot. 
i) BILE ACID CONJUGATE 
The effects of persulfated naringin-deoxycholic acid conjugate 16 and non-conjugated 
naringin persulfate (27) on APTT, PT, and TT are represented in Figure 40. The 
anticoagulant activity of the parent non-sulfated conjugate (15) and non-sulfated naringin 
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(8) was not possible to test due to their low water solubility. The % of dimethylsulfoxide 
(DMSO) necessary to solubilize the non-sulfated molecules resulted in precipitation of 
plasma proteins. 
Compound 16 showed potent anticlotting activity (Table 21). In the presence of 1 mM 
of compound 16, the formation of the fibrin clot was completely inhibited i.e., was not 
observed even after 180 s (APTT), 120 s (PT), and 240 s (TT) (Figure 40). At 160 μM, the 
clot formation after the activation of factor XII (APTT) was still inhibited and the TT was 
prolonged above the double (Figure 40). The concentration required to double the APPT 
(APTT2) was around 40 μM (Table 21). Additionally, compound 16 showed better 
anticoagulant activity when compared with other sulfated phenolic compounds previously 
synthesized in LQOF.74, 75, 138 
Non-conjugated naringin persulfate (27) also affected the APTT, PT, and TT in a dose-
dependent manner (Figure 40), however higher concentrations were necessary to achieve 
the same ratio, comparing with compound 16. Complete inhibition of APTT was only 
observed at 1 mM and the concentration able to double the APTT was around 200 μM 
(Table 21). So, conjugate 16 is more potent anticoagulant than compound 27. The 
conjugation not only retained but also increased the anticoagulant activity of compound 27. 
This result was expected because hydroxyl groups of the steroid were also sulfated.  
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Figure 40 - Dose-dependent effects of compounds 16 and 27 on APTT, PT, and TT clotting assays 
using human pooled plasma, expressed as ratio of clotting time in the presence/absence of 
compound. a clotting time values greater than 180s, b clotting time values greater than 120s, c clotting 
time values greater than 240s, * P < 0.05 
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Table 21 - Effects of sulfated compounds 16 and 27 on blood coagulation. 
 16 27 
APTT inhib.a (x10-3M) 0.16 1 
APTT2 (x10-3M) 0.0442 ± 0.0002 0.209 ± 0.005 
PT inhib.b (x10-3M) 1 - 
PT2 (x10-3M) 0.222 ± 0.050 - 
TT inhib.c (x10-3M) 1 - 
TT2 (x10-3M) 0.0864 ± 0.0007 - 
Tthe synthesis and anticoagulant activity of sulfated derivatives of deoxycholic acid (9) 
and 4’-naringin acetic acid (12) would be interesting to perform in order to compare with the 
conjugated compound 16. 
ii) TRIAZOLE LINKED XANTHONOSIDE 
The effects of 3,6-bis(1-(2-(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (22) on APTT, PT, and TT 
are represented in Figure 41. The anticoagulant activity of non-sulfated compound 21 was 
not possible to test due to their low water solubility. The % of DMSO necessary to solubilize 
the non-sulfated compound resulted in precipitation of plasma proteins. 
Prolongation of APTT, PT, and TT in the presence of compound 22 was observed in a 
dose-dependent manner. However, PT and TT were less affected than APTT. Sulfated 
derivative 22 exhibited an APTT2 of 129 ± 3 μM, PT2 of 739 ± 10 μM, and TT2 of 230 ± 3 
μM. These values were higher than the previous obtained for the non-triazole 3,6-(O-β-
glucopyranosyl) xanthone persulfate (2).75 
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Figure 41 - Dose-dependent effects of compound 22 on APTT, PT, and TT clotting assays using 
human pooled plasma, expressed as ratio of clotting time in the presence/absence of compound. a 
clotting time values greater than 180s. * P < 0.05. 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
75 
 
In contrast to bile acid conjugation strategy, the triazole introduction strategy seems 
to decrease the in vitro anticlotting activity, although it is worthy to perform permeability 
studies with Ussing chamber to test if compound 22 is able to cross the epithelial 
membrane. 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 - EXPERIMENTAL SECTION 
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3.1. GENERAL MATERIALS AND METHODS 
Commercial available reagents were purchased from Sigma Aldrich Co. and from 
Fluka. 3,6-Bis(prop-2-yn-yloxy)-9H-xanthen-9-one was synthesized in Laboratório de 
Química Orgânica e Farmacêutica da Faculdade de Farmácia, Universidade do Porto. 
Solvents used were products pro analysis or HPLC grade of the firms Sigma-Aldrich and 
Fluka. 
Reactions were controlled by TLC using Merck silica gel 60 (GF254) plates. 
Compounds were visually detected by absorbance at 254 and/or 365 nm and ferric chloride 
10% in MeOH or ninhydrin 3 mg/ml in EtOH following heat activation. MW reactions were 
performed using a MicroSYNTH 1600 from Millestone (ThermoUnicam, Portugal) 
synthesizer in sealed and open reaction vessels. 
Purification of compounds was carried out either by flash chromatography using Fluka 
silica gel 60 (0.04-0.063 mm) or preparative TLC using Merck silica gel 60 (GF254) plates. 
The qualitative purity of the synthesized compounds was determined by TLC using two 
different mobile phases. 
Melting points were obtained in a Köfler microscope and are uncorrected. IR spectra 
were measured on an ATI Mattson Genesis series FTIR (software: WinFirst v.2.10) 
spectrophotometer in KBr microplates (cm-1). 1H and 13C NMR spectra were performed in 
University of Aveiro, Department of Chemistry and were taken in CDCl3 and DMSO-d6, at 
room temperature, on Bruker Avance 300 instrument (300.13 MHz for 1H and 75.47 MHz 
for 13C). 13C NMR assignments were made by 2D HSQC and HMBC experiments (long-
range C, H coupling constants were optimized to 7 and 1 Hz). Chemical shifts are expressed 
in ppm values relative to tetramethylsilane (TMS) as an internal reference. Coupling 
constants are reported in hertz (Hz). HRMS mass spectra were measured on a APEX III 
mass spectrometer, recorded as ESI (Electrospray) made in Centro de Apoio Científico e 
Tecnolóxico á Investigation (CACTI, University of Vigo, Spain). 
Six human tumor cell lines were used to study antitumor activity: MCF-7 ER(+) (breast 
adenocarcinoma), NCI-H460 (non-small cell lung cancer), and A375-C5 (melanoma), U251 
(glioblastoma astrocytoma), U373 (glioblastoma astrocytoma) and U87MG glioblastoma 
astrocytoma). 
APTT, PT, and TT tests were performed using an STA Evolution coagulometer. The 
following commercial reagents were used: 00308 (Stago, França) for the APTT, 00665 
(Stago, França) for the PT and 00611 (Stago, França) for the TT. 
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3.2. SYNTHESIS 
3.2.1. Synthesis of mangiferin peracetate (6) 
Mangiferin (5, M3547, 0.2 g, 0.5 mmol) and iodine (0.009 g, 0.07 mmol) were mixed in 
acetic anhydride (7 mL) and the reaction was kept under MW irradiation (400W) at 130 ˚C 
for 15 minutes. After cooling, a saturated solution of sodium thiosulfate was added to 
transform iodine (dark yellow) into iodide (yellow). The crude product was extracted with 
CH2Cl2 and the organic layer was extracted with a saturated solution of NaHCO3 twice, dried 
with anhydrous Na2SO4, and filtered. The solvent was evaporated under reduced pressure 
and the oil obtained was dissolved in ethyl acetate and insolubilized with petroleum ether 
60-80˚C to afford 1,3,6,7-tetra-O-acetyl-2-C-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-
9H-xanthen-9-one (6) as a yellow solid (0.294 g, 0.39 mmol, 78% yield). mp 143-147 ˚C 
(petroleum ether 60-80˚C); IR (KBr) max: 2937, 1781, 1754, 1664, 1618, 1459, 1370, 1172 
cm-1; 1H NMR (CDCl3, 300.13 MHz) δ: 8.00 (1H, s, H-8), 7.39 (1H, s, H-5), 7.25 (1H, s, H-
4), 5.73 (1H, t, J=9.7 Hz, H-2’), 5.35-5.14 (2H, m, H-3´ and H-4’), 4.86 (1H, dd, J=4.9 and 
10.1 Hz, H-1´), 4.42 (1H, dd, J=4.2 and 12.6 Hz, H-6’b), 4.05-3.98 (1H, d, J=12.6 Hz) H-
6’a), 3.84-3.80 (1H, m, H-5’), 2.53 (3H, s, COCH3), 2.49 (3H, s, COCH3), 2.34 (3H, s, 
COCH3), 2.32 (3H, s, COCH3), 2.07 (3H, s, COCH3), 2.06 (3H, s, COCH3), 2.03 (3H, s, 
COCH3) 1.80 (3H, s, COCH3); 13C NMR (CDCl3, 75.47 MHz) δ: 174.0 (C-9), 170.6 
(OCOCH3), 170.5 (OCOCH3), 170.3 (OCOCH3), 169.6 (OCOCH3), 169.2 (OCOCH3), 168.5 
(OCOCH3), 168.0 (OCOCH3), 167.7 (OCOCH3), 167.2 (OCOCH3), 157.4 (C-4a), 154.4 (C-
3), 152.9 (C-1 and C-6), 147.7 (C-10a), 139.4 (C-7), 120.8 (C-8), 120.1 (C-8a), 118.3 (C-
2), 112.7 (C-5), 112.1 (9a), 111.7 (C-4), 76.6 (C-5’), 74.4 (C-3’), 72.5 (C-1’), 69.4 (C-2’), 
68.1 (C-4’), 61.9 (C-6’), 21.4 (OCOCH3), 21.3 (OCOCH3), 21.1 (OCOCH3), 20.8 (OCOCH3), 
20.7 (OCOCH3), 20.5 (OCOCH3), 20.4 (OCOCH3), 20.3 (OCOCH3). 
3.2.2. Synthesis of mangiferin heptaacetate (7) 
Mangiferin (5, M3547, 0.2 g, 4.7 mmol) was mixed with acetic anhydride (10 mL) and 
the mixture was heated at 130 ˚C for 3.5 hours. After cooling, the solution obtained was 
poured into ice and a saturated solution of NaHCO3, and extracted with CH2Cl2. Organic 
layer was dried with anhydrous Na2SO4, filtered and evaporated under reduced pressure. 
The crude oil obtained was further purified using flash chromatography (SiO2; hexane:ethyl 
acetate, 7:3) to give 1-hydroxy-3,6,7-tri-O-acetyl-2-C-(2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl)-9H-xanthen-9-one (7) as a light yellow solid (0.0378 g, 0.053 mmol, 11% 
yield). mp 160-162 ˚C (hexane/ethyl acetate); IR (KBr) max: 3443, 2919, 2850, 1779, 
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1746, 1647, 1619, 1467, 1372, 1229 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ: 13.25 (1H, s, 
1-OH), 8.06 (1H, s, H-8), 7.42 (1H, s, H-5), 6.76 (1H, s, H-4), 5.68 (1H, brs, H-2’), 5.35 (1H, 
t, J= 9.4 Hz, H-3'), 5.23-5.17 (2H, m, H-4’ and H-1'), 4.40 (1H, d, J= 11.6 Hz, H-6’b), 4.04-
4.00 (1H, m, H-6’a), 3.85-3.81 (1H, m, H-5’), 2.44 (3H, s, COCH3), 2.35 (3H, s, H- COCH3), 
2.34 (3H, s, COCH3), 2.07 (3H, s, COCH3), 2.05 (3H, s, COCH3), 2.02 (3H, s, COCH3) 1.78 
(3H, s, COCH3); 13C NMR (CDCl3, 75.47 MHz) δ: 180.4 (C-9), 170.5 (OCOCH3), 170.2 
(OCOCH3), 169.6 (OCOCH3), 169.2 (OCOCH3) 169.4 (OCOCH3), 168.0 (OCOCH3), 167.1 
(OCOCH3), 161.3 (C-1), 156.7 (C-4a), 153.9 (C-3),148.4 (C-6 and C10a), 139.4 (C-7), 120.1 
(C-8), 119.9 (C-8a) 118.4 (C-2), 112.9 (C-5), 110.6 (C-4), 106.0 (C-9a), 76.5 (C-5’), 74.5 
(C-3’), 73.3 (C-1’), 70.4 (C-4’), 68.3 (C-2’), 62.1 (C-6’), 22.7 (COCH3), 21.3 (COCH3), 20.7 
(COCH3), 20.7 (COCH3), 20.6 (COCH3), 20.5 (COCH3), 20.4 (COCH3). 
3.2.3. Synthesis of naringin-di-deoxycholate (10) 
DOCA (9, D2510, 0.338 g, 0.86 mmol, 1 eq.) and TBTU (Fluka 12806, 0.277 g, 0.86 mmol, 
1 eq.) were dissolved in tetrahydrofuran (THF) and TEA (1.72 mmol, 0.24 mL, 2 eq.) was 
added. After 15 minutes, naringin (8, N1376, 0.5 g, 0.86 mmol) was added. The mixture 
was kept under a nitrogen atmosphere at room temperature for 72 hours. The solution 
obtained was poured into ice and the solid formed was filtered and purified by flash 
chromatography (SiO2; CHCl3:MeOH:HCOOH, 8:2:0.1) and then by preparative TLC (SiO2; 
CHCl3:MeOH:HCOOH, 8:2:0.1) to give the ester derivate 10 (0.025 g, 0.0188 mmol, 2.2%) 
as white solid. mp 182-185 ˚C (H2O; IR (KBr) max: 3415, 2933, 2865, 1737, 1642, 1448, 
1374, 1087; 1H NMR (DMSO-d6, 300.13 MHz) δ: 12.03 (1H, s, 5-OH naringin), 7.56 (2H, d, 
J=8.1 Hz, H-2’, H-6’ naringin), 7.17 (2H, d, J=8.5 Hz, H-3’, H-5’ naringin), 6.15-6.09 (2H, m, 
H6, H-8 naringin), 5.70-5.61 (1H, m, H-2 naringin), 5.47 (1H, d, J=4.6 Hz, OH), 5.42 (2H, d, 
J=5.2 Hz, OH), 5.20-5.16 (1H, m, H-1’’’ neohesperidoside), 5.09 (1H, brd, H-1’’ 
neohesperidoside), 4.77-4.74 (1H, m, OH), 4.69 (1H, d, J=4.3 Hz, OH), 4.50-4.48 (3H, m, 
OH), 4.26 (2H, d, J=3.9 Hz, H-12), 4.18-4.16 (1H, m, OH), 4.07-4.00 (1H, m, OH), 3.82 (1H, 
d, J=2.9 Hz, 3-OH DOCA), 3.73-3.67 (6H, m, H-neohesperidoside, H-3 DOCA), 3.51-3.28 
(2H, m, H-neohesperidoside, under water), 3.23-3.16 (4H, m, H-neohesperidoside), 2.89-
2.87 (1H, m, H-3eq naringin), 2.83-2.81 (1H, m, H-3ax naringin), 2.28-2.18 (2H, H-23 DOCA), 
1.82-1.24 (56H, m, H-steroidal DOCA), 1.17 (3H, d, J=6.1 Hz, 6’’’-CH3 neohesperidoside), 
0.99 (6H, d, J=5.7, 21-CH3), 0.85 (6H, s, 19-CH3), 0.63 (3H, s, 18-CH3 DOCA), 0.56 (3H, s, 
18-CH3 DOCA); 13C NMR (DMSO-d6, 75.47 MHz) δ: 197.0 (C-4 naringin), 173.2 (C-24 
DOCA), 172.2 (C-24 DOCA), 163.0 (C-5 naringin), 162.8 (C-7 naringin), 150.7 (C-4’ 
naringin), 136.2 (C-1’ naringin), 128.0 (C-2’, C-6’ naringin), 122.0 (C-3’, C-5’ naringin), 100.7 
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(C-1’’), 97.0 (C-1’’ neohesperidoside, C-6/8 naringin), 95.0 (C-6/8 naringin) 77.0 (C-2 
naringin), 71.1 (C-neohesperidoside, C-12 DOCA), 70.4 (C-neohesperidoside), 70.0 (C-
neohesperidoside, C-3 DOCA), 68.0 (C-neohesperidoside), 47.5 (C-14 DOCA), 47.4 (C-14 
DOCA), 46.2 (C-17 DOCA), 46.1, 46.0 (C-13 DOCA), 41.6 (C-5 DOCA, C-3 naringin), 40.3, 
40.1, 39.8, 39.5, 39.2 (C-DOCA), 36.3 (C-8 DOCA), 35.7 (C-4 DOCA), 35.2 (C-20 DOCA), 
35.0 (C-1), 33.9 (C-10 DOCA), 33.0, 30.8 (C-23 DOCA), 30.6 (C-23 DOCA), 30.3 (C-2 
DOCA), 28.6 (C-11 DOCA), 27.3 (C-6 DOCA), 27.0 (C-16 DOCA), 26.1 (C-7 DOCA), 23.5 
(C-15 DOCA), 23.1 (C-19 DOCA), 18.1 (C-6’’’ neohesperidoside), 17.0 (C-21 DOCA), 16.7 
(C-21 DOCA), 12.5 (C-18 DOCA), 12.4 (C-18 DOCA). 
3.2.4. Synthesis of methyl 4’-naringin acetate (11) 
Naringin (8, N1376, 1 g, 1.72 mmol) was dissolved in DMF (20 mL) and K2CO3 (0.285 
g, 2.06 mmol, 1.2 eq.) was added. After 10 minutes, methyl bromoacetate (253 μL, 2.75 
mmol, 1.6 eq.) was added. The mixture was kept at room temperature for 32 hours. The 
solution obtained was evaporated under reduced pressure and the solid was purified by 
flash chromatography (SiO2:CHCl3:acetone) to give methyl 4’-(7-[[2-O-(6-Deoxy-α-L-
mannopyranosyl)-β-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-
4H-1-benzopyran-4-oxy)) acetate (11) as an orange solid (0.206 g; 0.32 mmol; 18% yield). 
mp 166-170 ˚ C (CHCl3:acetone); IR (KBr) max: 3420, 2922, 1754, 1632, 1511, 1439, 1216, 
1176, 1078, 832, 668; 1H NMR (DMSO-d6, 300.13 MHz) δ: 12.05 (1H, s, 5-OH), 7.46 (2H, 
dd, J=2.4 and 8.9 Hz, H-2’ and H6’), 7.02-6.97 (2H, m, H3’ and H-5’), 6.20 (1H, d, J=2.5 Hz, 
H-8), 6.13-6.08 (1H, m, H-6), 5.60-5.52 (1H, m, H-2), 5.15-5.10 (3H, m, H-1’’, H-1’’’ and 
OH), 4.91-4.87 (4H, m, OHs), 4.83 (2H, s, O-CH2), 3.74-3.64 (3H, m, H-5’’’, H-2’’’, and H-
6’’a), 3.71 (3H, s, O-CH3), under water (4H, m, H-2’’, H-3’’, H5’’ and H-6’’b), 3.23-3.15 (3H, 
m, H-3’’’, H-4’’’ and H-4’’), 2.82-2.73 (2H, m, H-3), 1.16 (3H, d, J=6.2 Hz, 6’’’-CH3); 13C NMR 
(DMSO-d6, 75.47 MHz) δ: 197.2 (C-4), 169.2 (COOCH3), 164.8 (C-7), 163.0 (C-5), 162.8 
(C-9), 157.9 (C-4’), 128.5 (C-1’), 128.4 (C-2’), 128.2 (C-6’), 115.1 (C-3’ and C-5’), 103.4 (C-
10), 100.5 (C-1’’), 97.3 (C-1’’’), 96.4 (C-6), 95.2 (C-8), 79.2 (C-2), 77.1 (C-2’’), 76.9 (C-5’’), 
76.1 (C-3’’), 71.8 (C-4’’’), 70.5 (C-2’’’), 70.4 (C-3’’’), 69.6 (C-4’’), 68.3 (C-5’’’), 65.4 (4’-OCH2), 
60.5 (C-6’’), 51.9 (OCH3), 45.4 (C-3), 18.1 (C-6’’’). 
3.2.5. Synthesis of 4’-naringin acetic acid (12) 
Compound 11 (0.207 g, 0.316 mmol) was dissolved in MeOH (4 mL) and sodium 
methoxide (0.5 M solution in MeOH, 3 mL, 1.5 mmol) was added. The mixture was kept at 
room temperature for 5 hours. After completion of the reaction, the solvent was evaporated 
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under reduced pressure and the product neutralized using a strong cationic exchange solid 
phase extraction column. H2O was evaporated under reduced pressure to give (7-[[2-O-(6-
deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-
hydroxyphenyl)-4H-1-benzopyran-4-oxy) acetic acid (12) as a dark yellow solid (0.199 g; 
0.313 mmol; 99% yield). mp 215 ˚C dec (H2O); IR (KBr) max: 3438, 2919, 1735, 1628, 
1512, 1424, 1348, 1215, 1177, 1128, 1072, 813; 1H NMR (DMSO-d6, 300.13 MHz) δ: 13.89 
(1H, s, COOH), 12.05 (1H, s, 5-OH), 7.44 (2H, dd, J=2.4 and 8.8 Hz, H-2’ and H-6’), 6.93 
(2H, d, J=8.8 Hz, H-3’ and H-5’), 6.16-6.08 (2H, m, H-6 and H-8), 5.61-5.53 (1H, m, H-2), 
5.17-5.05 (4H, m, H-1’’, H-1’’’, and 2OH), 4.62 (1H, d, J=3.5 Hz, OH), 4.57 (1H, d, J=4.4 
Hz, OH), 4.51 (1H, m, OH), 4.43-4.38 (1H, m, OH), 3.74-3.64 (2H, m, H-6’’a, H-5’’’), 3.49-
3.16 (1H, H-6’’b), 3.25-3.16 (3H, m, H-2’’’, H-3’’’, and H-4’’’), 2.82-2.71 (2H, m, H-3), 1.16 
(3H, d, J=6.2 Hz, 6’’’-CH3); 13C NMR (DMSO-d6, 75.47 MHz) δ: 197.2 (C-4), 170.1 (C=O), 
164.8 (C-7), 163.3 (C-5), 162.8 (C-9), 157.9 (C-4’), 128.5 (C-1’), 128.4 (C-2’), 128.3 (C-6’), 
115.0 (C-3’ and C-5’), 100.5 (C-1’’), 103.3 (C-10), 97.4 (C-1’’’), 96.3 (C-6), 95.2 (C-8), 78.9 
(C-2), 77.1 (C-2’’), 76.9 (C-5’’), 71.8 (C-4’’’), 70.5 (C-2’’’), 70.4 (C-3’’’), 69.6 (C-4’’), 68.3 (C-
5’’’), 65.3 (4’-OCH2), 60.5 (C-6’’), 42.0 (C-3), 18.1 (6’’’-CH3). 
3.2.6. Synthesis of succinimido deoxycholate (13) 
DOCA (9, D2510, 1 g, 2.12 mmol) was dissolved in THF (50 mL) and DCC (0.745 g, 
3.2 mmol, 1.7 eq./COOH) and NHS (0.416 g, 3.2 mmol, 1.7 eq./COOH) were added. The 
mixture was kept under nitrogen atmosphere, at room temperature, overnight. After 
completion of the reaction, insolubilized dicyclohexylurea was removed by filtration. The 
filtrate was concentrated under reduced pressure, hexane was added, and 2,5-
dioxopyrrolidin-1-yl (R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (13) insolubilized 
as a white solid (1.1 g, 2.25 mmol, 88% yield). IR (KBr) max: 3432, 2938, 2863, 1811, 
1781, 1741, 1448, 1207, 1066, 1043, 994, 648 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ: 4.00 
(1H, t, J= 2.8, 3-OH), 3.77-3.73 (1H, m, H-12), 3.98-3-56 (1H, m, H-3), 2.87-2.82 (4H, m, 
CH2-CH2, NHS), 2.67-2.55 (2H, m, H-23a and H-23b), 1.94-1.05 (32H, m, H-steroidal), 1.01 
(3H, d, J=6.1 Hz, 21-CH3), 0.91 (3H, s, 19-CH3), 0.70 (3H, s, 18-CH3); 13C NMR (CDCl3, 
75.47 MHz) δ: 169.1 (C-24), 169.2 (C=O, NHS), 73.1 (C-12), 71.8 (C-3), 48.2 (C-14), 47.1 
(C-17), 46.6 (C-13), 42.1 (C-5), 36.4 (C-8), 36.0 (C-4), 35.2 (C-20), 34.9 (C-1), 34.1 (C-10), 
33.7 (C-9), 30.5 (C-2, C-22, C-23), 28.0 (C-11), 27.4 (C-6), 27.1 (C-16), 26.1 (C-7), 25.6 
(CH2-CH2, NHS), 23.6 (C-15), 23.2 (C-19), 17.3 (C-21), 12.7 (C-18). 
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3.2.7. Synthesis of N-deoxycholylethylenediamine (14) 
Succinimido deoxycholate (13, 0.5 g, 1.02 mmol) was dissolved in DMF (2.5 mL) and 
EDA (5 mL) was added. The mixture was kept at room temperature for 24 hours. The 
solution obtained was poured into ice and  (R)-N-(2-aminoethyl)-4-
((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamide (14) insolubilized as a white solid (0.361 g, 
0.831 mmol, 81% yield). mp 120-123 ˚C (H2O); IR (KBr) max: 3628, 2926, 2861, 1694, 
1628, 1558, 1506, 1447, 1374, 671; 1H NMR (DMSO-d6, 300.13 MHz) δ: 7.72 (1H, t, J= 
10.9, NH), 4.49 (1H, s, 3-OH), 4.21 (1H, brd, H-12), 3.79 (1H, s, H-3), 3.01 (4H, q, J=6.3 
and 12.2, CH2-CH2), 2.13-2.04 (1H, m, H-23a), 2.00-1.90 (2H, m, H-23), 1.82-0.97 (31H, m, 
H-steroidal, -NH2), 0.92 (3H, d, J=6.2 Hz, 21-CH3), 0.84 (3H, s, 19-CH3), 0.59 (3H, s, 18-
CH3); 13C NMR (DMSO-d6, 75.47 MHz) δ: 172.7 (C-24), 71.0 (C-12), 70.0 (C-3), 47.5 (C-
14), 46.2 (C-17), 46.0 (C-13), 42.3 (C-5), 36.3 (C-8), 35.7 (C-4), 35.1 (C-1, C-20), 33.8 (C-
10), 32.9 (C-9, C-22), 32.5 (C-23), 28.7 (C-2), 28.6 (C-11), 27.2 (C-6), 27.0 (C-16), 26.1 (C-
7), 23.5 (C-15), 23.1 (C-19), 17.1 (C-21), 12.5 (C-18). 
3.2.8. Synthesis of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide 
(15) 
 Compound 12 (0.123 g, 0.192 mmol) and TBTU (Fluka 12806, 0.059 g, 0.385 mmol, 2 
eq.) were dissolved in DMF (7 mL) and TEA (54 μL, 0.385 mmol; 2 eq.) was added. After 
15 minutes, compound 14 (0.084 g, 0.192 mmol, 1 eq.) was added. The mixture was kept 
at room temperature for 48 hours. After the completion of the reaction the mixture was 
poured into ice and the solid was filtrated and washed with H2O, aqueous solution of HCl 
1M, and then with H2O to give (4R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-
dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-(2-(2-(4-
(7-[[2-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-
2-(4-hydroxyphenyl)-4H-1-benzopyran-4-oxy))acetamido)ethyl)pentanamide (15) as a 
yellow solid (0.149 g, 0.141 mmol, 73% yield). m.p 214-219 ˚C (H2O); IR (KBr) max: 3443, 
2924, 1633, 1384, 1176, 1076; 1H NMR (DMSO-d6, 300.13 MHz) δ: 12.06 (1H, s, 5-OH, 
naringin), 8.17 (1H, s, NH-amide), 7.87-7.79 (2H, m, H-2’/6’, NH amide), 7.49-7.45 (1H, brd, 
H-2’/6’ naringin), 7.03-6.99 (2H, brd, H-3’, H-5’), 6.21-6.10 (2H, m, H-6, H-8 naringin), 5.50-
5.54 (1H, m, H-2 naringin), 5.36-5.32 (1H, m, OH neohesperidoside), 5.18-5.10 (2H, m, H-
1’’, H-1’’’ neohesperidoside), 4.77-4.53 (6H, m, OH neohesperidoside, 3-OH DOCA, -OCH2-
), 4.19 (1H, s, H-12 doca), 3.77-3.69 (4H, m, H-neohesperidoside, H-3 DOCA), 3.55-3.35 
(6H, m, H-neohesperidoside, under water signal), 3.18-3.15 (4H, m, CH2CH2 EDA), 2.89-
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2.71 (2H, m, H-3 naringin), 2.07-1.91 (2H, m, H-23a, H23b DOCA), 1.75-1.14 (28H, m, H-
steroidal, 6’’’-CH3 neohesperidoside), 0.91 (3H, d, J=5.9 Hz, 21-CH3 DOCA) 0.84 (3H, s, 
19-CH3 DOCA), 0.59 (3H, s, 18-CH3 DOCA); 13C NMR (DMSO-d6, 75.47 MHz) δ: 174.3 
(C=O amide), 168.6 (C=O amide), 164.8 (C-7), 163.0 (C-5), 128.9 (C-2’, C-6’ naringin), 
115.6 (C-3’, C-5’, naringin), 100.9 (C-1’’, naeohesperidoside), 97.4 (C-1’’’, 
neohesperidoside), 96.8 (C-6,8 naringin), 77.4 (C-2 naringin), 76.6 (C-neohesperidoside), 
72.3 (C-neohesperidoside), 71.6 (C-neohesperidoside, C-12 DOCA), 70.7 (C-
neohesperidoside), 70.5 (C-neohesperidoside, C-3 DOCA), 68.8 (C-neohesperidoside), 
67.2 (-OCH2-), 60.9 (C-6’’, neohesperidoside), 47.8 (C-14, DOCA), 46.6 (C-17, DOCA), 46.4 
(C-13, C-3 DOCA), 42.0 (C-5, DOCA), 38.5 (CH2CH2-EDA), 36.5 (C- DOCA), 36.0 (C- 
DOCA), 35.4 (C-DOCA), 34.2 (C-DOCA), 33.3 (C-DOCA), 32.9 (C-DOCA), 32.0 (C-DOCA), 
31.9 (C-DOCA), 31.6 (C-23 DOCA), 30.4, 28.9 (C-DOCA), 27.6 (C-DOCA), 27.3 (C-DOCA), 
26.5 (C-DOCA), 23.9 (C-15, DOCA), 23.5 (C-19, DOCA), 18.4 (6’’’-CH3, naringin), 17.4 (C-
21, DOCA), 12.8 (C-18, DOCA). 
3.2.9. Synthesis of 4'-naringin (N-(2-deoxycholan-24-amidoethyl))acetamide 
persulfate (16) 
Compound 15 (0.138 g, 0.131 mmol) was dissolved in DMA (15 mL) and triethylamine-
sulfur trioxide (SO3:TEA) adduct (2.13 g, 11.8 mmol, 10 eq./OH) was added. The mixture 
was kept under MW irradiation (200W) at 100 ºC for 2 hours. After cooling, TEA was added 
until the pH was 8 and the obtained solution was poured into acetone and left at 4°C for 24 
hours. The crude oil formed was washed with acetone and ether to remove unreacted 
adduct and then was dissolved in aqueous solution of 30% NaOAc (2 mL). EtOH was added 
and the sodium salt of (4R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-di-O-sulfate-
10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-(2-(2-(4-(7-[[2-O-(6-
deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-
hydroxyphenyl)-4H-1-benzopyran-4-oxy)acetamido)ethyl)pentanamide (16) insolubilized 
as a light brown solid that was further purified by dialysis using a Spectra/Por 6 regenerated 
cellulose MWCO 1000 membrane (0.130 g, 0.066 mmol, 50% yield). m.p. 215-219 ˚C 
(EtOH); IR (KBr) max: 2921, 2863, 1632, 1558, 1240, 1058, 810; 1H NMR (DMSO-d6, 
300.13 MHz) δ: 8.24 (1H, s, NH-amide), 7.90 (2H, brd, H-2’/6’ naringin, NH amide), 7.49 
(1H, brd, H-2’/6’ naringin), 7.03 (2H, brd, H3’, H-5’ naringin), 6.19-5.98 (2H, m, H-6, H-8 
naringin), 5.35-5.20 (3H, m, H-2 naringin, H-1’’, H-1’’’ neohesperidoside), 4.75-4.68 (2H, m, 
H-neohesperidoside), 4.53-4.42 (6H, m, H-12 DOCA, H-neohesperidoside, -OCH2-), 4.01-
3.70 (6H, m, H-neohesperidoside, H-3 DOCA), 3.16-3.15 (4H, m, CH2CH2-EDA, H-
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neohesperidoside), 2.72-2.61 (2H, m, H-3, naringin), 2.13-2.09 (2H, m, H-23a, H-23b, 
DOCA) 1.90-1.16 (28H, m, H-steroidal, 6’’’-CH3 neohesperidoside), 0.94 (d, J=6.4 Hz, 21-
CH3 DOCA), 0.85 (3H, s, 19-CH3 DOCA), 0.62 (3H, s, 18-CH3 DOCA); 13C NMR (DMSO-
d6, 75.47 MHz) δ: 173.1 (C=O amide), 167.8 (C=O amide), 164.7 (C-7 naringin), 163.4 (C-
5 naringin), 131.0 (C-1’ naringin), 128.0 (C-2’, C-6’, naringin), 114.8 (C-3’, C-5’ naringin), 
100.8 (C-1’’ neohesperidoside), 97.3 (C-1’’’ neohesperidoside), 96.0 (C-6,8), 78.0 (C-2 
naringin, C-12 DOCA), 76.1 (C-neohesperidoside, C-3 DOCA), 71.5 (C-neohesperidoside), 
67.0 (-OCH2-), 48.2 (C-14 DOCA), 45.7 (C- DOCA), 45.6 (C-3 naringin, C-13 DOCA), 41.9 
(C-5 DOCA), 38.4 (CH2CH2-EDA), 38.2 (CH2CH2-EDA), 35.5 (C-4 DOCA), 35.3 (C-1 
DOCA), 33.9 (C-10 DOCA), 33.5-31.6 (C-DOCA), 27.3 (C-6 DOCA), 27.1 (C-16 DOCA), 
26.1 (C-7, DOCA), 24.5, 23.6 (C-15, DOCA), 23.2 (C-19, DOCA), 18.0 (C-6’’’, 
neohesperidoside), 17.4 (C-21, DOCA), 12.3 (C-18, DOCA). 
3.2.10. Synthesis of 3,6-bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (19) 
3,6-Bis(prop-2-yn-yloxy)-9H-xanthen-9-one (17, 0.183 g, 0.6 mmol) and 2-azidoethyl 
2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside (18, A1750, 0.499 g, 1.20 
mmol) were dissolved in THF/H2O (2:1, 20 mL) and sodium ascorbate (0.475 g, 2.40 mmol) 
and Cu2SO4.5H2O (0.3 g, 1.20 mmol) were added. The mixture was kept under MW 
irradiation (500 W) for 30 min at 70°C. After cooling, the reaction mixture was filtered, the 
THF of the filtrate was evaporated under reduced pressure, and the water suspension was 
extracted twice with ethyl acetate. A green solid was formed in the aqueous phase and after 
filtration 3,6-bis(1-(2-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)ethyl)-
1H-1,2,3-triazole-4-yl)methoxy)-9H-xanthen-9-one (19) was separated as an orange solid 
(0.497 g, 0.437 mmol, 73% yield). mp 239-241 ˚C (EtOAc); IR (KBr) max: 2957, 1745, 
1660, 1609, 1441, 1373; 1H NMR (DMSO-d6, 300.13 MHz) δ: 8.15 (1H, s, H-triazole), 8.09 
(1H, d, J=8.9 Hz, H-1/8), 7.92 (1H, d, J=9.1 Hz, NH-amide), 7.34 (1H, d, J=2.3 Hz, H-4/5), 
7.10 (1H, dd, J=2.3 and 9.0 Hz, H-2/7), 5.33 (2H, s, O-CH2-triazole), 5.07 (1H, t, J=9.8 Hz, 
H-5’/5’’), 4.85 (1H, t, J=9.9 Hz, H-3’/3’’), 4.70 (1H, d, J=8.5 Hz, H-1’/1’’), 4.60-4.57 (2H, m, 
N-CH2CH2-O), 4.21-4.02 (5H, m, H-4’/4’’, H6’/6’’a, H-6’/6’’b, N-CH2CH2-O), 3.76 (1H, q, 
J=9.7, H-2’/2’’), 2.02 (3H, s, COCH3), 1.97 (3H, s, COCH3), 1.91 (3H, s, COCH3), 1.71 (3H, 
s, NHOCH3); 13C NMR (DMSO-d6, 75.47 MHz) δ: 174.1 (C-9), 170.1 (COCH3), 169.7 
(COCH3), 169.4 (COCH3), 169.1 (NHCOCH3), 163.3 (C-3/6), 157.4 (C-4a/10a), 141.5 
(CH=C triazole), 127.5 (C-1/8), 125.2 (CH=C triazole), 115.0 (C-8a/9a), 113.8 (C-2/7), 101.5 
(C-4/5), 99.8 (C-1’/1’’), 72.5 (C-5’/5’’), 70.7 (C-4’/4’’), 68.4 (C-3’/3’’), 67.2 (N-CH2CH2-N), 
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61.9 (OCH2-triazole), 61.7 (C-6’/6’’), 52.8 (C-2’/2’’), 49.4 (N-CH2CH2-O), 22.6 (NHCOCH3), 
20.5 (COCH3), 20.4 (COCH3), 20.3 (COCH3). 
3.2.11. Synthesis of 3,6-bis(1-(2-(2-acetamido-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (20) 
Compound 19 (0.244 g; 0.215 mmol) was suspended in MeOH (8 mL) and MeONa (1 
mL) was added. The mixture was kept under stirring at room temperature for 3 hours. The 
mixture was filtered and 3,6-bis(1-(2-(2-acetamido-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-
1,2,3-triazole-4-yl)methoxy)-9H-xanthen-9-one (20) was obtained as a light green solid 
(0.162 g; 0.183 mmol, 86% yield). m.p. 238-240 ˚C (MeOH); IR (KBr) max: 3415, 2919, 
1648, 1610, 1444, 1375; 1H NMR (DMSO-d6, 300.13 MHz) δ: 8.18 (1H, s, H-triazole), 8.10 
(1H, d, J=9.0 Hz, H-1/8), 7.70 (1H, d, J=8.9 Hz, NH-amide), 7.35 (1H, d, J=2.1 Hz, H-4/5), 
7.12 (1H, dd, J=2.1 and 12 Hz H-2/7), 5.33 (2H, s, OCH2-triazole), 5.08 (1H, brd, OH), 5.01 
(1H, brd, OH), 4.60-4.57 (3H, m, N-CH2CH2-O, OH), 4.33 (1H, d, J=8.4 Hz, H-1’/1’’), 4.12-
4.08 (1H, m, N-CH2CH2-O), 3.87-3.81 (1H, m, N-CH2CH2-O), 3.73-3.68 (1H, m, H-6’/6’’), 
3.49-3.40 (1H, m, H-2’/2’’), 3.29-3.25 (1H, m, H-4’/4’’), 3.18-3.04 (2H, m, H3’/3’’ and H-5’/5’’) 
1.76 (3H, s, NHCOCH3); 13C NMR (DMSO-d6, 75.47 MHz) δ: 174.1 (C-9), 169.3 
(NHCOOCH3), 163.3 (C-3/6), 157.4 (C4a/10a), 141.6 (CH=C-triazole), 127.5 (C-1/C-8), 
125.5 (CH=C-triazole), 115.2 (C-8a/9a), 113.8 (C-2/7), 101.5 (C-4/5), 100.7 (C-1’/1’’), 77.1 
(C-5’/5’’), 74.1 (C-4’/4’’), 70.5 (C-3’/3’’), 66.5 (N-CH2CH2-N), 61.9 (O-CH2-triazole), 61.0 (C-
6’/6’’), 55.1 (C-2’/C-2’’), 49.6 (N-CH2CH2-O), 23.0 (NHCOOCH3). 
3.2.12. Synthesis of 3,6-bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (21) 
Compound 20 (0.155 g, 0.18 mmol) was suspended in an aqueous solution of NaOH 
20% (15 mL). The mixture was heated at 100ºC for 4 hours. After cooling, the mixture was 
purified by dialysis using a Spectra/Por 6 regenerated cellulose MWCO 1000 membrane to 
give 3,6-bis(1-(2-(2-amino-3,4,6-hydroxy-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-
triazole-4-yl)methoxy)-9H-xanthen-9-one (21) as a dark green solid (0.051 g, 0.064 mmol, 
36% yield). mp 157-159 ˚C (H2O); IR (KBr) max: 3362, 2920, 2880, 1641, 1609, 841; 1H 
NMR (DMSO-d6, 300.13 MHz) δ: 8.37 (1H, s, H-triazole), 8.08 (1H, d, J=8.9 Hz, H-1/8), 
7.33 (1H, brd, H-4/5), 7.11 (1H, d, J= 8.8 Hz, H-2/7), 5.35 (2H, s, OCH2-triazole), 5.04 (1H, 
brd, OH), 4.96 (1H, s, OH), 4.62-4.55 (3H, m, N-CH2-CH2-O, OH), 4.12-4.10 (2H, m, N-
CH2-CH2, H1’/1’’), 3.91-3.87 (1H, m, N-CH2-CH2), 3.71-3.67 (2H, m, H-6’/6’’a,b), 3.11-3.04 
(4H, m, H- 2’/2’’,H-3’/3’’, H-4’/4’’, H-5’/5’’) 1.44 (2H, s, NH2); 13C NMR (DMSO-d6, 75.47 
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MHz) δ: 174.0 (C-9), 163.3 (C-3/6), 157.5 (C-4a/10a), 141.7 (CH=C-triazole), 127.6 (C-1/8), 
125.8 (CH=C-triazole), 115.2 (C-8a/9a), 113.9 (C-2/C-7), 101.5 (C-4/C-5, C-1’/1’’), 77.2 (C-
5’/C-5’’), 76.5 (C-4’/4’’) 70.9 (C-3’/3’’), 67.3 (N-CH2CH2-O), 61.9 (O-CH2-triazole), 61.1 (C-
6’/C-6’’), 49.8 (C-2’/2’’), 49.6 (N-CH2CH2-O). 
3.2.13. Synthesis of 3,6-bis(1-(2-(2-amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-
glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-yl)methoxy)xanthone (22) 
Compound 21 (0.045 g, 0.05 mmol) was dissolved in DMA (5 mL) and the mixture was 
kept under MW irradiation for 15 minutes. Then, SO3:TEA adduct (0.046 g, 0.057 mmol, 10 
eq./OH and NH2) was added. The reaction solution was kept MW irradiation (200W) at 100 
ºC for 2 hours. After cooling, TEA was added until the pH was 8 and the obtained solution 
was poured into acetone and left at 4ºC for 24 hours. The crude oil formed was washed 
with acetone and ether to remove unreacted adduct and then was dissolved in aqueous 
solution of 30% NaOAc (2 mL). EtOH was added and the sodium salt of 3,6-bis(1-(2-(2-
amino-3,4,6-tri-O-sulfate-2-deoxy-β-D-glucopyranosyl)ethyl)-1H-1,2,3-triazole-4-
yl)methoxy)-9H-xanthen-9-one (22) insolubilized as a dark brown solid that was further 
purified by dialysis using a Spectra/Por 6 regenerated cellulose MWCO 1000 membrane 
(0.055 g, 0.04 mmol, 78% yield); mp 192 ˚C dec (H2O); IR (KBr) max: 2917, 2847, 1642, 
1619, 1257, 1047, 814; 1H NMR (DMSO-d6, 300.13 MHz) δ: 8.27 (1H, s, CH=C-triazole), 
8.07 (1H, d, J=8.8 Hz, H-1/8), 7.35 (1H, brd, H4/5), 7.13 (1H, d, J=7.5 Hz, H-2/7), 5.33 (2H, 
s, OCH2-triazole), 4.63-4.60 (2H, m, N-CH2CH2-O), 4.15-4.08 (3H, m, H-1’/1’’, N-CH2CH2-
O), 3.84-3.30 (3H, m, H-2/2’, H-3’/3’’, H-4’/4’’ and H5’/5’’, under water), 1.73 (2H, s, NH2); 
13C NMR (DMSO-d6, 75.47 MHz) δ: 174.2 (C-9), 163.4 (C3/6), 157.5 (C-4a/10a), 141.7 
(CH=C-triazole), 127.5 (C-1/8), 125.5 (CH=C-triazole), 115.2 (C-8a/9a), 113.9 (C-2/7), 
101.5 (C-4/5), 100.5 (C-1’/1’’), 76.9 (C-5’/5’’), 74.5 (C-4’/4’’), 70.5 (C-3’/3’’), 66.1 (N-
CH2CH2-N), 61.9 (O-CH2-triazole), 60.9 (C-6’/6’’), 53.0 (C-2’/2’’), 49.5 (N-CH2CH2-N). 
3.2.14. Synthesis of diosmin peracetate (24) 
Diosmin (23, D3525, 0.05 g, 0.08 mmol) and NaF (0.42 g, 10 mmol) were mixed in 
acetic anhydride (4 mL) and the mixture was kept under MW irradiation (400W) at 130ºC 
for 35 minutes. After cooling, the solution obtained was poured into ice and then extracted 
with CH2Cl2. The organic layer was extracted with NaHCO3, dried over anhydrous Na2SO4 
and filtered. Crystallization from MeOH/H2O furnished 5,3-O-acetyl-2-(3-O-acetyl-4-
methoxyphenyl)-7-[2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl-(1→6)-2,3,4-tri-O-acetyl-β-D-
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glucopyranosyloxy]oxychromen-4-one (24) as a yellow solid (0.048 g, 0.051 mmol, 62% 
yield). mp 135-138 ˚C; IR (KBr) max: 2940, 1754, 1644, 1614, 1514, 1433, 1371, 1289, 
982 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ: 7.72 (1H, dd, J= 2.3, 9.0 Hz, H-6’), 7.56 (1H, d, 
J= 2.3 Hz, H-2’), 7.08 (1H, d, J= 8.8 Hz, H-5’), 6.96 (1H, d, J= 2.4, H-8), 6.65 (1H, d, J= 2.4, 
H-6), 6.51 (1H, s, H-3), 5.37-5.15 (6H, m, H-1’’, H-2’’, H-3’’, H-4’’, H-3’’’, H-4’’’), 5.05-4.97 
(1H, m, H-2’’’), 4.72 (1H, s, H-1’’’), 4.01-3.95 (1H, m, H-5’’’), 3.91 (3H, s, 4’-OCH3), 3.85-
3.80 (2H, m, H-5’’, 6’’a), 3.70-3.65 (1H, m, H-6’’b), 2.43 (3H, s, COCH3), 2.36 (3H, s, 
COCH3), 2.17 (3H, s, COCH3), 2.09-2.02 (16H, m, COCH3), 1.92 (3H, s, COCH3), 1.15 (3H, 
d, J=6.2, H-6’’’); 13C NMR (CDCl3, 75.47 MHz) δ: 176.2 (C-4), 170.2 (COCH3), 170.0 
(COCH3), 169.9 (COCH3), 169.8 (COCH3), 169.7 (COCH3), 169.4 (COCH3), 169.3 
(COCH3), 168.8 (COCH3), 161.5 (C-7), 159.8 (C-2, C-5), 154.0 (C-4’), 150.7 (C-9), 140.1 
(C-3’), 123.9 (C-1’), 121.0 (C-6’), 112.8 (C-5’), 112.5 (C-2’), 109.0 (C-3), 102.4 (C-10), 98.1 
(C-6, C-1’’’), 97.8 (C-8, C-1’’), 73.5 (C-5’’), 72.4 (C-3’’), 70.9 (C-2’’), 70.8 (C-4’', C-4’’’), 69.3 
(C-2’’’), 68.9 (C-3’’’), 68.6 (C-6’’), 66.7 (C-5’’’), 56.2 (4’-OCH3), 31.0 (COCH3), 29.7 
(COCH3), 21.1 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.6 (COCH3),17.3 
(C-6’’’). 
3.2.15. Synthesis of rutin peracetate (26) 
Rutin (25, R2303, 0.3 g, 0.5 mmol) was mixed with acetic anhydride (12 mL) and the 
mixture was heated at 130˚C until completion of the reaction confirmed by TLC. The solution 
obtained was poured into ice and extracted with CH2Cl2. The organic layer was extracted 
with a saturated solution of NaHCO3, dried with anhydrous Na2SO4, filtered, and then 
evaporated under reduced pressure. The obtained oil was dissolved in ethyl acetate and 
insolubilized with petroleum ether 60-80˚C and 2-(3,4-di-O-acetylphenyl)-5,7-di-O-acetyl-3-
[3,4,5-tri-O-acetyl-α-L-rhamnopyranosyl-(1→6)-3,4,5-tri-O-acetyl-β-D-glucopyranosyloxy]-
4H-chromen-4-one (26) was obtained as a white solid (0.43 g, 0.41 mmol, 73% yield). mp 
119-120 ˚ C (petroleum ether 60-80˚C); IR (KBr) max: 2940, 1781, 1754, 1628, 1505, 1477, 
1435, 1371, 1145 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ: 7.96 (1H, dd, J=2.2 and 8.6 Hz, 
H-6’), 7.91 (1H, d, J=2.1 Hz, H-2’), 7.34 (1H, d, J=8.6 Hz, H-5’), 7.31 (1H, d, J=2.2 Hz, H-
8), 6.83 (1H, d, J=2.2 Hz, H-6), 5.43 (1H, d, J=7.8 Hz, H-1’’), 5.28 (1H, t, J=9.6 Hz, H-3’’), 
5.17 (1H, dd, J=7.8 and 9.8 Hz, H-2’’), 5.09-5.06 (2H, m, H-2’’’, H-3’’’), 4.95 (2H, t, J=9.7 
Hz, H-4’’, 4’’’), 4.52 (1H, brs, H-1’’’), 3.67-3.62 (1H, m, H-5’’’), 3.60-3.54 (1H, m, H-5’’), 3.53 
(1H, dd, J=3.1 and 12.5 Hz, H-6a), 3.26 (1H, dd, J=5.9 and 11.3 Hz, H-6’’b), 2.44 (3H, s, 
COCH3), 2.35 (3H, s, OCOCH3), 2.34 (3H, s, OCOCH3), 2.30 (3H, s, COCH3), 2.14 (3H, s, 
COCH3), 2.09 (3H, s, COCH3), 2.03 (6H, s, COCH3), 1.96 (3H, s, COCH3), 1.94 (3H, s, 
COCH3), 1.60 (3H, s, COCH3), 1.06 (3H, d, J=6.2 Hz, H-6’’’); 13C NMR (CDCl3, 75.47 MHz) 
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δ: 171.9 (C-4), 170.2 (COCH3), 169.9 (COCH3), 169.9 (COCH3), 169.8 (COCH3), 169.8 
(COCH3), 169.6 (COCH3), 169.3 (COCH3), 168.1 (COCH3), 167.9 (COCH3), 167.8 
(COCH3), 156.6 (C-2), 154.7 (C9), 153.9 (C-7), 150.2 (C-5), 144.1 (C-4’), 141.8 (C-3’), 136.9 
(C-3), 128.6 (C-1’), 127.2 (C-6’), 124.7 (C-2’), 123.5 (C-5’), 115.1 (C-10), 113.4 (C-6), 109.1 
(C-8), 99.6 (C-1’’), 97.7 (C-1’’’), 72.8 (C-5’’), 72.5 (C-3’’), 71.4 (C-2’’), 70.9 (C-4’’’), 69.5 (C-
4’’), 69.3 (C-2’’’), 69.0 (C-3’’’), 66.9 (C-6’’), 66.3 (C-5’’’), 21.2 (COCH3), 21.1 (COCH3), 20.9 
(COCH3), 20.9 (COCH3), 20.7 (COCH3), 20.7 (COCH3), 20.7 (COCH3), 20.6 (COCH3), 17.2 
(C-6’’’). 
3.2.16. Synthesis of naringin persulfate (27) 
Naringin (8, N1376, 0.5 g, 0.86 mmol) was dissolved in DMA (10 mL) and SO3:TEA 
adduct (9.37 g; 51.6 mmol; 6 eq./OH) was added. The mixture was kept under MW 
irradiation (200W) at 100°C for 1 hour. After cooling, TEA was added until the pH was 8 and 
the obtained solution was poured into acetone and left at 4°C for 24 hours. The crude oil 
formed was washed with acetone and ether to remove unreacted adduct and then dissolved 
in aqueous solution of 30% NaOAc (4 mL). EtOH was added and the sodium salt of 7-[[2-
O-(3,4,6-tri-O-sulfate-6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2,3-di-O-
sulfate-5-O-sulfate-2-(4-O-sulfatephenyl)-4H-1-benzopyran-4-one (27) insolubilized as 
yellow solid that was further purified by dialysis using a Spectra/Por 6 regenerated cellulose 
MWCO 1000 membrane (0.579 g; 0.41 mmol; 48% yield). mp 218-222 ˚C (H2O); IR (KBr) 
max: 1637, 1518, 1254, 1052, 810; 1H NMR (DMSO-d6, 300.13 MHz) δ: 7.58 (2H, d, J=8.8 
Hz, H-2’,6’), 7.17 (2H, d, J=8.7 Hz, H-3’, 5’), 6.20-6.18 (1H, brd, H-6), 6.04-5.95 (1H, m, H-
8), 5.31-5.23 (2H, m, H-1’’, 1’’’), 4.71-4.69 (1H, brd, H-2), 4.56 (1H, d, J=3.1 Hz, H-
neohesperidoside), 4.48 (1H, s, H-neohesperidoside) 4.29-4.21 (2H, m, H-
neohesperidoside), 4.07-3.94 (3H, m, H-neohesperidoside), 3.82-3.71 (3H, m, H-
neohesperidoside), 3.38-3.13 (2H, m, H-3, under water), 1.27 (3H, d, J=6.1 Hz, 6’’’-CH3); 
13C NMR (DMSO-d6, 75.47 MHz) δ: 197.3 (C-4), 161.3 (C-7, C-9), 157.0 (C-5), 155.6 (C-
4’), 129.8 (C-2’, C-6’), 129.5 (C-1’), 120.1 (C-3’, C-5’), 101.7 (C-10), 97.5 (C-6), 96.1 (C-1’’), 
96.0 (C-8), 95.5 (C-1’’’), 95.2 (C-8), 79.0 (C-2), 76.9-75.3 (3 C-neohesperidoside), 75.0 (C-
4’’’), 74.3-67.6 (4 C-neohesperidoside), 67.0 (C-5’’’), 40.0 (C-3, under DMSO), 18.1 (C-6’’’). 
HRMS (ESI+) m/z calcd for C27H24O38S8Na9 1418.6785, found 1418.67605. 
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3.2. BIOLOGICAL ACTIVITY 
3.2.1. Anticoagulant activity 
Clotting times were performed in Laboratório de Medicina Laboratorial Dr Carlos da 
Silva Torres, Grupo Unilabs, with the technical support of Vítor Marques. Human blood was 
collected from 7 healthy donors aged between 22 and 30 years old without history of 
bleeding or thrombosis and who had not taken any medication known to affect blood 
coagulation and platelet function for 2 weeks. Venous blood was obtained and transferred 
to a plastic tube. Nine volumes of blood were decalcified with one volume of 3.8% sodium 
citrate solution. Blood was centrifuged for 20 min at 2400g and the pooled plasma was 
stored in aliquots at -20 °C until use. Sulfated compounds were dissolved in saline solution. 
The final concentration of sulfated compounds in these assays ranged from 1.0×10-3 to 
2.56×10-5 M. Saline was used as control.  
Activated partial thromboplastin time (APTT): The assay was carried out according 
to the respective instructions of the manufacture: citrated normal human plasma mixed (1:1) 
with sample solution (50 μL), and APTT assay reagent (50 μL) and the mixture was 
incubated for 6 min at 37°C. CaCl2 (50 μL, 25 mmol/L) was added, and clotting times were 
recorded during 180 s. The APTT reagent used was the synthetic phospolipid cephaline 
with extract of rabbit brain tissue, and a polyphenolic activator. 
Prothrombin time (PT): The assay was carried out according to the respective 
instructions of the manufacture: citrated normal human plasma mixed (1:1) with sample 
solution (50 μL) was incubated. Then PT assay reagent (100 μL) was added and clotting 
times were recorded during 120 s. 
Thrombin time (TT): The assay was carried out according to the respective 
instructions of the manufacture: citrated normal human plasma mixed (1:1) with sample 
solution (100 μL) was incubated for 2 min at 37°C. Then 100 μL of thrombin solution (100 
U/mL), was added and clotting times were recorded during 240 s. The TT reagent used was 
100 U/mL of human calcic thrombin. 
The clotting times were recorded in seconds (s). Independent experiences were 
performed. Coagulation time prolonging ratio was calculated comparing the clotting time in 
the presence of each concentration of tested compound with that obtained when saline was 
used instead of test compound. The concentration required to double the clotting time was 
calculated from linear regression analysis of each individual concentration-response curve. 
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For clotting time values greater than 240 s (TT), 180 s (APTT), and 120 s (PT), values of 
240, 180, and 120 s, respectively, were arbitrarily assigned for statistical analysis. 
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3.2.2. Statistical analysis 
Statistical significance of the difference between control and treated samples was 
calculated by unpaired t test using GraphPad Prism 6 software. A value of P < 0.05 was 
considered significant. 
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Considering the general objectives of this work, the synthesis of new anticoagulant 
analogues of polysulfated small-molecules with improved oral bioavailability, the main 
achievements are as following: 
 sixteen compounds were obtained by different synthetic methods and ten were 
characterized for the first time; 
 copper(I)-catalyzed alkyne-azide 1,4-cycloaddition and sulfation syntheses were 
successfully assisted with MW irradiation; 
 screening of antitumor activity of some synthetic intermediates revealed a promising 
hit compound, peracetylated derivative 26, that deserves further investigation; 
 persulfated conjugate of naringin with bile acid 16 and persulfated xanthone triazole-
linked glycoside 22 exhibited anticoagulant activity; persulfated naringin-bile acid 
conjugate 16 was the most potent anticoagulant compound synthesized in LQOF. 
The conjugate of naringin with the bile acid DOCA 16 and the xanthone triazole-linked 
to a glycoside 22 are expected to cross the GI tract membrane: conjugate 16 will be 
recognized by bile acid transporters and the triazole in compound 22 is expected to increase 
lipophilicity. 
Taking in account the results obtained in this dissertation, the study of the permeability 
of the synthesized sulfated compounds would be important to perform. 
Improving permeability of polysulfated small-molecules could be a step forward to the 
development of orally active heparin-like antithrombotic drugs. 
  
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 - REFERENCES 
 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
99 
 
1. Kerns, E. H.; Di, L., Chapter 2 - Advantages of Good Drug-like Properties. In Drug-
like Properties: Concepts, Structure Design and Methods, Kerns, E. H.; Di, L., Eds. 
Academic Press: San Diego, 2008; pp 6-16. 
2. Zawilska, J. B.; Wojcieszak, J.; Olejniczak, A. B., Prodrugs: a challenge for the drug 
development. Pharmacol. Rep. 2013, 65 (1), 1-14. 
3. C. G. Wermuth, C. R. G., P. Lindberg and L. A. Mitscher, Glossary of terms used in 
medicinal chemistry (IUPAC Recommendations 1998). Pure Appl. Chem. 1998, 70 (5), 
1129-1143. 
4. Derek R. Buckle, P. W. E., C. Robin Ganellin, Toshi Kobayashi, Thomas J. Perun, 
John Proudfoot, Joerg Senn-Bilfinger, Glossary of terms used in medicinal chemistry. Part 
II (IUPAC Recommendations 2013). Pure Appl. Chem. 2013, 85 (8), 1725–1758. 
5. Fazen, C. H.; Valentin, D.; Fairchild, T. J.; Doyle, R. P., Oral Delivery of the Appetite 
Suppressing Peptide hPYY(3–36) through the Vitamin B12 Uptake Pathway. J. Med. Chem. 
2011, 54 (24), 8707-8711. 
6. Kim, S. K.; Lee, D. Y.; Lee, E.; Lee, Y.-k.; Kim, C. Y.; Moon, H. T.; Byun, Y., 
Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-
coagulant. J. Controll. Release 2007, 120 (1–2), 4-10. 
7. Clardy-James, S.; Chepurny, O. G.; Leech, C. A.; Holz, G. G.; Doyle, R. P., 
Synthesis, Characterization and Pharmacodynamics of Vitamin-B12-Conjugated Glucagon-
Like Peptide-1. ChemMedChem 2013, 8 (4), 582-586. 
8. Pore, V. S.; Aher, N. G.; Kumar, M.; Shukla, P. K., Design and synthesis of 
fluconazole/bile acid conjugate using click reaction. Tetrahedron 2006, 62 (48), 11178-
11186. 
9. Tolle-Sander, S.; Lentz, K. A.; Maeda, D. Y.; Coop, A.; Polli, J. E., Increased 
Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Mol. Pharm. 2004, 1 (1), 40-48. 
10. Petrus, A. K.; Vortherms, A. R.; Fairchild, T. J.; Doyle, R. P., Vitamin B12 as a carrier 
for the oral delivery of insulin. ChemMedChem 2007, 2 (12), 1717-21. 
11. Balakrishnan, A.; Polli, J. E., Apical Sodium Dependent Bile Acid Transporter 
(ASBT, SLC10A2): A Potential Prodrug Target. Mol. Pharm. 2006, 3 (3), 223-230. 
12. Petrus, A. K.; Fairchild, T. J.; Doyle, R. P., Traveling the vitamin B12 pathway: oral 
delivery of protein and peptide drugs. Angew. Chem. Int. Ed. Engl. 2009, 48 (6), 1022-8. 
13. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. 
D., Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. 
Chem. 2002, 45 (12), 2615-2623. 
14. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv. Drug Del. Rev. 2001, 46 (1-3), 3-26. 
15. Bauer, K. A., Pros and cons of new oral anticoagulants. Hematology Am. Soc. 
Hematol. Educ. Program 2013, 2013, 464-70. 
16. Ludwig, R. J., Therapeutic use of heparin beyond anticoagulation. Curr. Drug 
Discov. Technol. 2009, 6 (4), 281-9. 
17. Varki, N. M.; Varki, A., Heparin inhibition of selectin-mediated interactions during the 
hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. 
Semin. Thromb. Hemost. 2002, 28 (1), 53-66. 
18. Wang, L.; Brown, J. R.; Varki, A.; Esko, J. D., Heparin’s anti-inflammatory effects 
require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J. 
Clin. Invest. 2002, 110 (1), 127-136. 
19. Linhardt, R. J., 2003 Claude S. Hudson Award Address in Carbohydrate Chemistry. 
Heparin:  Structure and Activity. J. Med. Chem. 2003, 46 (13), 2551-2564. 
20. Page, C., Heparin and Related Drugs: Beyond Anticoagulant Activity. ISRN 
Pharmacol. 2013, 2013, 13. 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
100 
 
21. Lugemwa, F.; Shaikh, K.; Hochstedt, E., Facile and Efficient Acetylation of Primary 
Alcohols and Phenols with Acetic Anhydride Catalyzed by Dried Sodium Bicarbonate. 
Catalysts 2013, 3 (4), 954-965. 
22. Leone–Bay, A.; Paton, D. R.; Weidner, J. J., The development of delivery agents 
that facilitate the oral absorption of macromolecular drugs. Med. Res. Rev. 2000, 20 (2), 
169-186. 
23. Weitz, J. I., Low-Molecular-Weight Heparins. New Engl. J. Med. 1997, 337 (10), 688-
699. 
24. Hirsh, J.; Levine, M., Low molecular weight heparin. Blood 1992, 79 (1), 1-17. 
25. Pirmohamed, M., Warfarin: almost 60 years old and still causing problems. Br. J. 
Clin. Pharmacol. 2006, 62 (5), 509-511. 
26. Arbit, E.; Goldberg, M.; Gomez-Orellana, I.; Majuru, S., Oral heparin: Status review. 
Thromb. J. 2006, 4 (6). 
27. Chakrabarti, R.; Das, S. K., Advances in antithrombotic agents. Cardiovasc. 
Hematol. Agents Med. Chem. 2007, 5 (3), 175-185. 
28. Jaques, L. B., Heparins-anionic polyelectrolyte drugs. Pharmacol. Rev. 1979, 31 (2), 
99-166. 
29. Qi, Y.; Zhao, G.; Liu, D.; Shriver, Z.; Sundaram, M.; Sengupta, S.; Venkataraman, 
G.; Langer, R.; Sasisekharan, R., Delivery of therapeutic levels of heparin and low-
molecular-weight heparin through a pulmonary route. Proc. Natl. Acad. Sci. U. S. A. 2004, 
101 (26), 9867-9872. 
30. Blanchfield, J. T.; Toth, I., Modification of peptides and other drugs using lipoamino 
acids and sugars. Methods Mol. Biol. 2005, 298, 45-61. 
31. Gomez-Orellana, I., Strategies to improve oral drug bioavailability. Expert Opinion 
on Drug Delivery 2005, 2 (3), 419-433. 
32. Hylemon, P. B.; Zhou, H.; Pandak, W. M.; Ren, S.; Gil, G.; Dent, P., Bile acids as 
regulatory molecules. J. Lipid Res. 2009, 50 (8), 1509-1520. 
33. Lee, Y.-k.; Kim, S. K.; Lee, D. Y.; Lee, S.; Kim, C.-Y.; Shin, H.-C.; Moon, H. T.; Byun, 
Y., Efficacy of orally active chemical conjugate of low molecular weight heparin and 
deoxycholic acid in rats, mice and monkeys. J. Control. Release 2006, 111 (3), 290-298. 
34. Lee, Y.; Nam, J. H.; Shin, H. C.; Byun, Y., Conjugation of low-molecular-weight 
heparin and deoxycholic acid for the development of a new oral anticoagulant agent. 
Circulation 2001, 104 (25), 3116-20. 
35. Lee, Y.-k.; Kim, S.; Byun, Y., Oral Delivery of New Heparin Derivatives in Rats. 
Pharm. Res. 2000, 17 (10), 1259-1264. 
36. Eom, J. S.; Koh, K. S.; Al-Hilal, T. A.; Park, J. W.; Jeon, O. C.; Moon, H. T.; Byun, 
Y., Antithrombotic efficacy of an oral low molecular weight heparin conjugated with 
deoxycholic asset on microsurgical anastomosis in rats. Thromb. Res. 2010, 126 (3), 220-
224. 
37. Kim, S. K.; Vaishali, B.; Lee, E.; Lee, S.; Lee, Y.-k.; Kumar, T. S.; Moon, H. T.; Byun, 
Y., Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous 
formulation. Thromb. Res. 2006, 117 (4), 419-427. 
38. Park, J. W.; Jeon, O. C.; Kim, S. K.; Al-Hilal, T. A.; Moon, H. T.; Kim, C. Y.; Byun, 
Y., Anticoagulant Efficacy of Solid Oral Formulations Containing a New Heparin Derivative. 
Mol. Pharm. 2010, 7 (3), 836-843. 
39. Park, K.; Kim, K.; Kwon, I. C.; Kim, S. K.; Lee, S.; Lee, D. Y.; Byun, Y., Preparation 
and Characterization of Self-Assembled Nanoparticles of Heparin-Deoxycholic Acid 
Conjugates. Langmuir 2004, 20 (26), 11726-11731. 
40. Kim, S. K.; Kim, K.; Lee, S.; Park, K.; Park, J. H.; Kwon, I. C.; Choi, K.; Kim, C.-Y.; 
Byun, Y., Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using 
a surface plasmon resonance. J. Pharm. Biomed. Anal. 2005, 39 (5), 861-870. 
41. Moon, H.; Jeon, O.; Byun, Y.; Kim, Y.; Lee, Y.-K., Evaluation of the oral absorption 
of heparin conjugated with sodium deoxycholate as a facilitating agent in GI tract. 
Macromol. Res. 2009, 17 (2), 79-83. 
 101 
 
42. Khatun, Z.; Nurunnabi, M.; Cho, K. J.; Lee, Y.-k., Imaging of the GI tract by QDs 
loaded heparin–deoxycholic acid (DOCA) nanoparticles. Carbohydr. Polym. 2012, 90 (4), 
1461-1468. 
43. Paliwal, R.; Paliwal, S. R.; Agrawal, G. P.; Vyas, S. P., Biomimetic Solid Lipid 
Nanoparticles for Oral Bioavailability Enhancement of Low Molecular Weight Heparin and 
Its Lipid Conjugates: In Vitro and in Vivo Evaluation. Mol. Pharm. 2011, 8 (4), 1314-1321. 
44. Park, J. W.; Kim, S. K.; Al-Hilal, T. A.; Jeon, O. C.; Moon, H. T.; Byun, Y., Strategies 
for oral delivery of macromolecule drugs. Biotechnol. Bioprocess Eng. 2010, 15 (1), 66-75. 
45. Tsukita, S.; Furuse, M.; Itoh, M., Multifunctional strands in tight junctions. Nat. Rev. 
Mol. Cell Biol. 2001, 2 (4), 285-293. 
46. Al-Hilal, T. A.; Alam, F.; Byun, Y., Oral drug delivery systems using chemical 
conjugates or physical complexes. Adv. Drug Deliv. Rev. 2013, 65 (6), 845-864. 
47. Bernkop-Schnürch, A.; Kast, C.; Guggi, D., Permeation enhancing polymers in oral 
delivery of hydrophilic macromolecules: thiomer/GSH systems. J. Control. Release 2003, 
93 (2), 95-103. 
48. Krug, S. M.; Amasheh, M.; Dittmann, I.; Christoffel, I.; Fromm, M.; Amasheh, S., 
Sodium caprate as an enhancer of macromolecule permeation across tricellular tight 
junctions of intestinal cells. Biomaterials 2013, 34 (1), 275-282. 
49. Motlekar, N. A.; Srivenugopal, K. S.; Wachtel, M. S.; Youan, B. B., Oral delivery of 
low-molecular-weight heparin using sodium caprate as absorption enhancer reaches 
therapeutic levels. J. Drug Target. 2005, 13 (10), 573-83. 
50. Motlekar, N. A.; Srivenugopal, K. S.; Wachtel, M. S.; Youan, B. B. C., Evaluation of 
the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid 
as permeation enhancer. Drug Dev. Res. 2006, 67 (2), 166-174. 
51. Imai, T.; Sakai, M.; Ohtake, H.; Azuma, H.; Otagiri, M., In Vitro and In Vivo 
Evaluation of the Enhancing Activity of Glycyrrhizin on the Intestinal Absorption of Drugs. 
Pharm. Res. 1999, 16 (1), 80-86. 
52. Hisamitsu Pharmaceutical Co., I. 
http://www.hisamitsu.co.jp/english/company/corporate/history.html (accessed 30-05-2014). 
53. Jiang, L.; Wang, Q.; Shen, S.; Xiao, T.; Li, Y., Discovery of glycyrrhetinic acid as an 
orally active, direct inhibitor of blood coagulation factor xa. Thromb. Res. 2014, 133 (3), 
501-6. 
54. Aungst, B. J., Intestinal permeation enhancers. J. Pharm. Sci. 2000, 89 (4), 429-
442. 
55. Thanou, M.; Verhoef, J.; Junginger, H., Oral drug absorption enhancement by 
chitosan and its derivatives. Adv. Drug Deliv. Rev. 2001, 52 (2), 117-126. 
56. Thanou, M.; Nihot, M.; Jansen, M.; Verhoef, J. C.; Junginger, H., Mono‐N‐
carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the 
intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and 
in vivo. J. Pharm. Sci. 2001, 90 (1), 38-46. 
57. Thanou, M.; Henderson, S.; Kydonieus, A.; Elson, C., N-sulfonato-N,O-
carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of 
macromolecules. J. Control. Release 2007, 117 (2), 171-178. 
58. Kast, C. E.; Guggi, D.; Langoth, N.; Bernkop-Schnurch, A., Development and in vivo 
evaluation of an oral delivery system for low molecular weight heparin based on thiolated 
polycarbophil. Pharm. Res. 2003, 20 (6), 931-6. 
59. Bernkop-Schnürch, A., Thiomers: A new generation of mucoadhesive polymers. 
Adv. Drug Deliv. Rev. 2005, 57 (11), 1569-1582. 
60. Pineo, G.; Hull, R.; Marder, V., Oral delivery of heparin: SNAC and related 
formulations. Best Pract. Res. Clin. Haematol. 2004, 17 (1), 153-60. 
61. Malkov, D.; Wang, H. Z.; Dinh, S.; Gomez-Orellana, I., Pathway of oral absorption 
of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm. Res. 2002, 19 (8), 
1180-4. 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
102 
 
62. Berkowitz, S. D.; Marder, V. J.; Kosutic, G.; Baughman, R. A., Oral heparin 
administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients 
undergoing elective total hip arthroplasty. J. Thromb. Haemost. 2003, 1 (9), 1914-1919. 
63. Salartash, K.; Gonze, M. D.; Leone-Bay, A.; Baughman, R.; Sternbergh Iii, W. C.; 
Money, S. R., Oral low–molecular weight heparin and delivery agent prevents jugular 
venous thrombosis in the rat. J. Vasc. Surg. 1999, 30 (3), 526-532. 
64. Emisphere Technologies, I., Emisphere Technologies Announces Clinical Data On 
Solid Oral Heparin Formulations. 
http://ir.emisphere.com/releasedetail.cfm?ReleaseID=356222, 2002; Vol. 2014. 
65. Hayes, P. Y.; Ross, B. P.; Thomas, B. G.; Toth, I., Polycationic lipophilic-core 
dendrons as penetration enhancers for the oral administration of low molecular weight 
heparin. Biorg. Med. Chem. 2006, 14 (1), 143-52. 
66. Lee, D. Y.; Lee, J.; Lee, S.; Kim, S. K.; Byun, Y., Liphophilic complexation of heparin 
based on bile acid for oral delivery. J. Control. Release 2007, 123 (1), 39-45. 
67. Abdelrahim, A. S.; Ziora, Z. M.; Bergeon, J. A.; Moss, A. R.; Toth, I., Design and 
synthesis of a series of novel, cationic liposaccharide derivatives as potential penetration 
enhancers for oral drug delivery. Tetrahedron 2009, 65 (45), 9436-9442. 
68. Jiao, Y.; Ubrich, N.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Lecompte, T.; 
Maincent, P., In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles 
in rabbits. Circulation 2002, 105 (2), 230-5. 
69. Hoffart, V.; Ubrich, N.; Simonin, C.; Babak, V.; Vigneron, C.; Hoffman, M.; Lecompte, 
T.; Maincent, P., Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles: 
Formulation, Characterization, and Release Characteristics. Drug Dev. Ind. Pharm. 2002, 
28 (9), 1091-1099. 
70. Hoffart, V.; Ubrich, N.; Lamprecht, A.; Bachelier, K.; Vigneron, C.; Lecompte, T.; 
Hoffman, M.; Maincent, P., Microencapsulation of Low Molecular Weight Heparin into 
Polymeric Particles Designed with Biodegradable and Nonbiodegradable Polycationic 
Polymers. Drug Deliv. 2003, 10 (1), 1-7. 
71. Hoffart, V.; Lamprecht, A.; Maincent, P.; Lecompte, T.; Vigneron, C.; Ubrich, N., Oral 
bioavailability of a low molecular weight heparin using a polymeric delivery system. J. 
Control. Release 2006, 113 (1), 38-42. 
72. Jiao, Y. Y.; Ubrich, N.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Maincent, 
P., Preparation and In Vitro Evaluation of Heparin-Loaded Polymeric Nanoparticles. Drug 
Deliv. 2001, 8 (3), 135-141. 
73. Goldberg, M.; Gomez-Orellana, I., Challenges for the oral delivery of 
macromolecules. Nat. Rev. Drug Discov. 2003, 2 (4), 289-295. 
74. Correia-da-Silva, M.; Sousa, E.; Duarte, B.; Marques, F.; Carvalho, F.; Cunha-
Ribeiro, L. M.; Pinto, M. M., Flavonoids with an oligopolysulfated moiety: a new class of 
anticoagulant agents. J. Med. Chem. 2011, 54 (1), 95-106. 
75. Correia-da-Silva, M.; Sousa, E. l.; Duarte, B. r.; Marques, F.; Carvalho, F. l.; Cunha-
Ribeiro, L. s. M.; Pinto, M. M. M., Polysulfated Xanthones: Multipathway Development of a 
New Generation of Dual Anticoagulant/Antiplatelet Agents. J. Med. Chem. 2011, 54 (15), 
5373-5384. 
76. Correia-da-Silva, M.; Sousa, E.; Duarte, B.; Marques, F.; Cunha-Ribeiro, L. M.; 
Pinto, M. M. M., Dual anticoagulant/antiplatelet persulfated small molecules. Eur. J. Med. 
Chem. 2011, 46 (6), 2347-2358. 
77. Correia-da-Silva, M.; Sousa, E.; Duarte, B.; Marques, F.; Cunha-Ribeiro, L. M.; 
Pinto, M. M., Dual anticoagulant/antiplatelet persulfated small molecules. Eur. J. Med. 
Chem. 2011, 46 (6), 2347-58. 
78. Correia-da-Silva, M.; Sousa, E.; Duarte, B.; Marques, F.; Carvalho, F.; Cunha-
Ribeiro, L. M.; Pinto, M. M., Flavonoids with an oligopolysulfated moiety: a new class of 
anticoagulant agents. J. Med. Chem. 2011, 54 (1), 95-106. 
 103 
 
79. Kushwaha, K.; Kaushik, N.; Lata; Jain, S. C., Design and synthesis of novel 2H-
chromen-2-one derivatives bearing 1,2,3-triazole moiety as lead antimicrobials. Bioorg. 
Med. Chem. Lett. 2014, 24 (7), 1795-1801. 
80. Sheng, C.; Che, X.; Wang, W.; Wang, S.; Cao, Y.; Miao, Z.; Yao, J.; Zhang, W., 
Design and synthesis of novel triazole antifungal derivatives by structure-based 
bioisosterism. Eur. J. Med. Chem. 2011, 46 (11), 5276-5282. 
81. Barber, C. G.; Blakemore, D. C.; Chiva, J.-Y.; Eastwood, R. L.; Middleton, D. S.; 
Paradowski, K. A., 1-Amido-1-phenyl-3-piperidinylbutanes – CCR5 antagonists for the 
treatment of HIV: Part 2. Bioorg. Med. Chem. Lett. 2009, 19 (5), 1499-1503. 
82. Negi, J. S.; Bisht, V. K.; Singh, P.; Rawat, M. S. M.; Joshi, G. P., Naturally Occurring 
Xanthones: Chemistry and Biology. J. Appl. Chem. 2013, 2013, 9. 
83. Dar, A.; Faizi, S.; Naqvi, S.; Roome, T.; Zikr-ur-Rehman, S.; Ali, M.; Firdous, S.; 
Moin, S. T., Analgesic and Antioxidant Activity of Mangiferin and Its Derivatives: the 
Structure Activity Relationship. Biol. Pharm. Bull. 2005, 28 (4), 596-600. 
84. Stoilova I., G. S., Stoyanova A., Ho I., Antimicrobial and antioxidant activity of the 
polyphenol mangiferin. Herba Pol. 2005, 51 (1-2). 
85. Sánchez, G. M.; Re, L.; Giuliani, A.; Núñez-Sellés, A. J.; Davison, G. P.; León-
Fernández, O. S., Protective effects of Mangifera indica L. extract, mangiferin and selected 
antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage 
activation in mice. Pharmacol. Res. 2000, 42 (6), 565-573. 
86. Miura, T.; Ichiki, H.; Hashimoto, I.; Iwamoto, N.; Kao, M.; Kubo, M.; Ishihara, E.; 
Komatsu, Y.; Okada, M.; Ishida, T.; Tanigawa, K., Antidiabetic activity of a xanthone 
compound, mangiferin. Phytomedicine 2001, 8 (2), 85-87. 
87. Muruganandan, S.; Srinivasan, K.; Gupta, S.; Gupta, P. K.; Lal, J., Effect of 
mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J. 
Ethnopharmacol. 2005, 97 (3), 497-501. 
88. Zheng, M. S.; Lu, Z. Y., Antiviral effect of mangiferin and isomangiferin on herpes 
simplex virus. Chin. Med. J. (Engl.) 1990, 103 (2), 160-5. 
89. Wang, R.-R.; Gao, Y.-D.; Ma, C.-H.; Zhang, X.-J.; Huang, C.-G.; Huang, J.-F.; 
Zheng, Y.-T., Mangiferin, an Anti-HIV-1 Agent Targeting Protease and Effective against 
Resistant Strains. Molecules 2011, 16 (5), 4264. 
90. Li, X.-J.; Du, Z.-C.; Huang, Y.; Liu, B.-M.; Hu, W.-J.; Lu, W.-J.; Deng, J.-G., 
Synthesis and hypoglycemic activity of esterified-derivatives of mangiferin. Chin. J. Nat. 
Med. 2013, 11 (3), 296-301. 
91. Han, J.; Yi, J.; Liang, F.; Jiang, B.; Xiao, Y.; Gao, S.; Yang, N.; Hu, H.; Xie, W.-F.; 
Chen, W., X-3, a mangiferin derivative, stimulates AMP-activated protein kinase and 
reduces hyperglycemia and obesity in db/db mice. Mol. Cell. Endocrinol. 2015, 405, 63-73. 
92. Hu, H. G.; Wang, M. J.; Zhao, Q. J.; Yu, S. C.; Liu, C. M.; Wu, Q. Y., Synthesis of 
mangiferin derivates and study their potent PTP1B inhibitory activity. Chin. Chem. Lett. 
2007, 18 (11), 1323-1326. 
93. Hu, H.-g.; Wang, M.-j.; Zhao, Q.-j.; Liao, H.-l.; Cai, L.-z.; Song, Y.; Zhang, J.; Yu, S.-
c.; Chen, W.-s.; Liu, C.-m.; Wu, Q.-y., Synthesis of mangiferin derivatives as protein tyrosine 
phosphatase 1B inhibitors. Chem. Nat. Compd. 2007, 43 (6), 663-666. 
94. Singh, S. K.; Kumar, Y.; Kumar, S. S.; Sharma, V. K.; Dua, K.; Samad, A., 
Antimicrobial evaluation of mangiferin analogues. Indian J. Pharm. Sci. 2009, 71 (3), 328-
31. 
95. Singh, S. K.; Tiwari, R. M.; Sinha, S. K.; Danta, C. C.; Prasad, S. K., Antimicrobial 
evaluation of mangiferin and its synthesized analogues. Asian Pac. J. Trop. Biomed. 2012, 
2 (2, Supplement), S884-S887. 
96. Kant Singh, S.; Sinha, S. K.; Prasad, S. K.; Kumar, R.; Bithu, B. S.; Sadish Kumar, 
S.; Singh, P., Synthesis and evaluation of novel analogues of mangiferin as potent 
antipyretic. Asian Pac. J. Trop. Med. 2011, 4 (11), 866-869. 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
104 
 
97. Gómez-Zaleta, B.; Ramírez-Silva, M. T.; Gutiérrez, A.; González-Vergara, E.; 
Güizado-Rodríguez, M.; Rojas-Hernández, A., UV/vis, 1H, and 13C NMR spectroscopic 
studies to determine mangiferin pKa values. Spectrochim. Acta Mol. Biomol. Spectrosc. 
2006, 64 (4), 1002-1009. 
98. Mattarei, A.; Biasutto, L.; Rastrelli, F.; Garbisa, S.; Marotta, E.; Zoratti, M.; Paradisi, 
C., Regioselective O-derivatization of quercetin via ester intermediates. An improved 
synthesis of rhamnetin and development of a new mitochondriotropic derivative. Molecules 
2010, 15 (7), 4722-36. 
99. Wei, X.; Liang, D.; Ning, M.; Wang, Q.; Meng, X.; Li, Z., Semi-synthesis of 
neomangiferin from mangiferin. Tetrahedron Lett. 2014, 55 (19), 3083-3086. 
100. Mogilaiah, K.; Rani, J. U.; Vidya, K.; Sakram, B., Microwave-promoted rapid and 
efficient method for acetylation of phenols with acetic anhydride using NaF as catalyst under 
solvent-free conditions. Orient. J. Chem. 2009, 25 (1), 187. 
101. Li, J.; Zhang, L.-P.; Peng, F.; Bian, J.; Yuan, T.-Q.; Xu, F.; Sun, R.-C., Microwave-
Assisted Solvent-Free Acetylation of Cellulose with Acetic Anhydride in the Presence of 
Iodine as a Catalyst. Molecules 2009, 14 (9), 3551-3566. 
102. Nanduri, S.; Nyavanandi, V. K.; Sanjeeva Rao Thunuguntla, S.; Kasu, S.; Pallerla, 
M. K.; Sai Ram, P.; Rajagopal, S.; Ajaya Kumar, R.; Ramanujam, R.; Moses Babu, J.; Vyas, 
K.; Sivalakshmi Devi, A.; Om Reddy, G.; Akella, V., Synthesis and structure–activity 
relationships of andrographolide analogues as novel cytotoxic agents. Bioorg. Med. Chem. 
Lett. 2004, 14 (18), 4711-4717. 
103. Mojtahedi, M. M.; Samadian, S., Efficient and Rapid Solvent-Free Acetylation of 
Alcohols, Phenols, and Thiols Using Catalytic Amounts of Sodium Acetate Trihydrate. J. 
Chem. 2013, 2013. 
104. Patnam, R.; Chang, F.-R.; Kuo, R.-Y.; Pan, W.-B.; Wu, Y.-C., Microwave enhanced 
acetylation of alcohols. J. Chem. Res. 2002, 2002 (6), 301-302. 
105. Phukan, P., Iodine as an extremely powerful catalyst for the acetylation of alcohols 
under solvent-free conditions. Tetrahedron Lett. 2004, 45 (24), 4785-4787. 
106. Jin, T.-S.; Ma, Y.-R.; Zhang, Z.-H.; Li, T.-S., Sulfamic acid catalysed acetylation of 
alcohols and phenols with acetic anhydride. Synth. Commun. 1998, 28 (17), 3173-3177. 
107. Heravi, M. M.; Behbahani, F. K.; Shoar, R. H.; Oskooie, H. A., Ferric perchlorate: A 
novel and highly efficient catalyst for direct acetylation of THP ethers with acetic acid. J. 
Mol. Catal. A: Chem. 2006, 244 (1–2), 8-10. 
108. Ahmed, N.; van Lier, J. E., Molecular iodine in isopropenyl acetate (IPA): a highly 
efficient catalyst for the acetylation of alcohols, amines and phenols under solvent free 
conditions. Tetrahedron Lett. 2006, 47 (30), 5345-5349. 
109. Bosco, J. W. J.; Agrahari, A.; Saikia, A. K., Molecular iodine catalyzed selective 
acetylation of alcohols with vinyl acetate. Tetrahedron Lett. 2006, 47 (24), 4065-4068. 
110. Wang, R. E.; Kao, J. L. F.; Hilliard, C. A.; Pandita, R. K.; Roti, J. L. R.; Hunt, C. R.; 
Taylor, J.-S., Inhibition of Heat Shock Induction of Heat Shock Protein 70 and Enhancement 
of Heat Shock Protein 27 Phosphorylation by Quercetin Derivatives. J. Med. Chem. 2009, 
52 (7), 1912-1921. 
111. Al-Majedy, Y.; Kadhum, A.; Al-Amiery, A.; Mohamad, A., Synthesis and 
Characterization of Some New 4-Hydroxy-coumarin Derivatives. Molecules 2014, 19 (8), 
11791-11799. 
112. Sachdeva, A. K.; Kuhad, A.; Chopra, K., Naringin ameliorates memory deficits in 
experimental paradigm of Alzheimer's disease by attenuating mitochondrial dysfunction. 
Pharmacol. Biochem. Behav. 2014, 127, 101-10. 
113. Kandhare, A. D.; Raygude, K. S.; Ghosh, P.; Ghule, A. E.; Bodhankar, S. L., 
Neuroprotective effect of naringin by modulation of endogenous biomarkers in 
streptozotocin induced painful diabetic neuropathy. Fitoterapia 2012, 83 (4), 650-659. 
114. Schindler, R.; Mentlein, R., Flavonoids and Vitamin E Reduce the Release of the 
Angiogenic Peptide Vascular Endothelial Growth Factor from Human Tumor Cells. J. Nutr. 
2006, 136 (6), 1477-1482. 
 105 
 
115. Choi, M. S.; Do, K. M.; Park, Y. S.; Jeon, S. M.; Jeong, T. S.; Lee, Y. K.; Lee, M. K.; 
Bok, S. H., Effect of naringin supplementation on cholesterol metabolism and antioxidant 
status in rats fed high cholesterol with different levels of vitamin E. Ann. Nutr. Metab. 2001, 
45 (5), 193-201. 
116. Seo, H. J.; Jeong, K. S.; Lee, M. K.; Park, Y. B.; Jung, U. J.; Kim, H. J.; Choi, M. S., 
Role of naringin supplement in regulation of lipid and ethanol metabolism in rats. Life Sci. 
2003, 73 (7), 933-46. 
117. Balalaie, S.; Mahdidoust, M.; Eshaghi-Najafabadi, R., 2-(1H-Benzotriazole-1-yl)-
1,1,3,3-Tetramethyluronium Tetrafluoro Borate (TBTU) as an Efficient Coupling Reagent for 
the Esterification of Carboxylic acids with Alcohols and Phenols at Room Temperature. 
Chin. J. Chem . 2008, 26 (6), 1141-1144. 
118. Wang, Z., Zemplén Deacetylation. In Comprehensive Organic Name Reactions and 
Reagents, John Wiley & Sons, Inc.: 2010. 
119. Balalaie, S.; Mahdidoust, M.; Eshaghi-Najafabadi, R., 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate as an efficient coupling reagent for the 
amidation and phenylhydrazation of carboxylic acids at room temperature. JICS 2007, 4 
(3), 364-369. 
120. Correia-da-Silva, M.; Sousa, E.; Pinto, M. M. M., Emerging Sulfated Flavonoids and 
other Polyphenols as Drugs: Nature as an Inspiration. Med. Res. Rev. 2013, 34 (2), 223-
279. 
121. Al-Horani, R. A.; Desai, U. R., Chemical Sulfation of Small Molecules – Advances 
and Challenges. Tetrahedron 2010, 66 (16), 2907-2918. 
122. Raghuraman, A.; Riaz, M.; Hindle, M.; Desai, U. R., Rapid and efficient microwave-
assisted synthesis of highly sulfated organic scaffolds. Tetrahedron Lett. 2007, 48 (38), 
6754-6758. 
123. Liang, L.; Astruc, D., The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) 
“click” reaction and its applications. An overview. Coord. Chem. Rev. 2011, 255 (23–24), 
2933-2945. 
124. Greene, T. W., Wuts, P. G. M., Protective groups in organic synthesis. 3rd ed.; John 
Wiley and Sons, Inc.: New York, 1998. 
125. Mabey, W.; Mill, T., Critical review of hydrolysis of organic compounds in water 
under environmental conditions. J. Phys. Chem. Ref. Data 1978, 7 (2), 383-415. 
126. Sultane, P. R.; Mete, T. B.; Bhat, R. G., Chemoselective N-deacetylation under mild 
conditions. Org. Biomol. Chem. 2014, 12 (2), 261-264. 
127. Shimizu, Y.; Morimoto, H.; Zhang, M.; Ohshima, T., Microwave-assisted deacylation 
of unactivated amides using ammonium-salt-accelerated transamidation. Angew. Chem. 
Int. Ed. Engl. 2012, 51 (34), 8564-7. 
128. Faizi, S.; Zikr-ur-Rehman, S.; Ali, M.; Naz, A., Temperature and solvent dependent 
NMR studies on mangiferin and complete NMR spectral assignments of its acyl and methyl 
derivatives. Magn. Reson. Chem. 2006, 44 (9), 838-844. 
129. Mabry, T.; Markham, K. R.; Thomas, M. B., The NMR Spectra of Flavonoids. In The 
Systematic Identification of Flavonoids, Springer Berlin Heidelberg: 1970; pp 274-343. 
130. Velandia, J. R.; de Carvalho, M. G.; Braz-Filho, R.; Werle, A. A., Biflavonoids and a 
glucopyranoside derivative from Ouratea semiserrata. Phytochem. Anal 2002, 13 (5), 283-
292. 
131. Cárdenas, M.; Marder, M.; Blank, V. C.; Roguin, L. P., Antitumor activity of some 
natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. 
Biorg. Med. Chem. 2006, 14 (9), 2966-2971. 
132. Zhu, Z.-Y.; Wang, W.-X.; Wang, Z.-q.; Chen, L.-J.; Zhang, J.-Y.; Liu, X.-c.; Wu, S.-
p.; Zhang, Y.-m., Synthesis and antitumor activity evaluation of chrysin derivatives. Eur. J. 
Med. Chem. 2014, 75, 297-300. 
133. Plaza, C.; Pavani, M.; Araya-Maturana, R.; Pezoa, J.; Maya, J. D.; Morello, A.; 
Becker, M. I.; De Ioannes, A.; Ferreira, J., Chemosensitizing Effect of Nordihydroguaiaretic 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
106 
 
Acid and its Tetra-acetylated Derivative on Parental and Multiresistant TA3 Mouse 
Mammary Adenocarcinoma Cells. In Vivo 2009, 23 (6), 959-967. 
134. Meng, L.-Z.; Huang, W.-H.; Wang, C.-Z.; Yuan, C.-S.; Li, S.-P., Anticancer Activities 
of Polyynes from the Root Bark of Oplopanax horridus and Their Acetylated Derivatives. 
Molecules 2014, 19 (5), 6142. 
135. Bulotta, S.; Corradino, R.; Celano, M.; Maiuolo, J.; D'Agostino, M.; Oliverio, M.; 
Procopio, A.; Filetti, S.; Russo, D., Antioxidant and antigrowth action of peracetylated 
oleuropein in thyroid cancer cells. J. Mol. Endocrinol. 2013, 51 (1), 181-189. 
136. Ignjatovic, V., Prothrombin Time/International Normalized Ratio. In Haemostasis, 
Monagle, P., Ed. Humana Press: 2013; Vol. 992, pp 121-129. 
137. Ignjatovic, V., Thrombin Clotting Time. In Haemostasis, Monagle, P., Ed. Humana 
Press: 2013; Vol. 992, pp 131-138. 
138. Correia-da-Silva, M.; Sousa, E.; Duarte, B.; Marques, F.; Cunha-Ribeiro, L. M.; 
Pinto, M. M., Dual anticoagulant/antiplatelet persulfated small molecules. Eur. J. Med. 
Chem. 2011, 46 (6), 2347-58. 
139. Waterhous, D. V.; Barnes, S.; Muccio, D. D., Nuclear magnetic resonance 
spectroscopy of bile acids. Development of two-dimensional NMR methods for the 
elucidation of proton resonance assignments for five common hydroxylated bile acids, and 
their parent bile acid, 5 beta-cholanoic acid. J. Lipid Res. 1985, 26 (9), 1068-78. 
140. Kamst, E.; Zegelaar-Jaarsveld, K.; van der Marel, G. A.; van Boom, J. H.; 
Lugtenberg, B. J. J.; Spaink, H. P., Chemical synthesis of N-acetylglucosamine derivatives 
and their use as glycosyl acceptors by the Mesorhizobium loti chitin oligosaccharide 
synthase NodC. Carbohydr. Res. 1999, 321 (3–4), 176-189. 
141. Correia-da-Silva, M. Flavonóides Sulfatados: obtenção, determinação estrutural e 
actividades biológicas. Universidade do Porto, Porto, 2006. 
  
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 – APPENDICES 
  
  
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
109 
 
APPENDIX I - 1H and 13C NMR data for compounds 5 (DMSO-d6), 6 (CDCl3), and 7 (CDCl3). 
The NMR data of compound 5 is in accordance with the literature.75 Values of chemical shift (δ) in parts 
per million (ppm). J values (Hz) are presented in parentheses. 
 
  
 
5 6 7 
1H 13C 1H 13C 1H 13C 
1 - 161.8 - 152.9 - 161.3 
2 - 107.7 - 118.3 - 118.4 
3 - 163.9 - 154.4 - 153.9 
4 6.38 (s) 93.3 7.25 (s) 111.7 6.76 (s) 110.6 
4a  156.2 - 157.4 - 156.7 
5 6.87 (s) 102.7 7.39 (s) 112.7 7.42 (s) 112.9 
6 - 154.1 - 152.9 - 148.4 
7 - 143.8 - 139.4 - 139.4 
8 7.38 (s) 108.1 8.00 (s) 120.8 8.06 (s) 120.1 
8a - 111.7 - 120.1 - 119.9 
9 - 179.1 - 174.4 - 180.4 
9a - 150.8 - 112.1 - 106.0 
10a - 101.3 - 147.7 - 148.4 
1’ 4.59 (d, J=9.7) 73.1 
4.86 (dd, 
J=10.1, 4.9) 
72.5 5.23-5.17 (m) 73.3 
2’ 4.06 (t, J=9.2) 70.2 5.73 (t, J=9.7) 69.4 5.68 (brs) 68.3 
3’ 3.26-3.09 (m) 79.0 5.35-5.14 (m) 74.4 5.35 (t, J=9.4) 74.5 
4’ 3.26-3.09 (m) 70.7 5.35-5.14 (m) 68.1 5.23-5.17 (m) 70.4 
5’ 3.26-3.09 (m) 81.7 3.84-3.80 (m) 76.6 3.85-3.81 (m) 76.5 
6’a 
3.69 (d, 
J=11.1) 
61.5 
4.05-3.98 (d, 
J=12.6) 
61.9 
4.04-4.00 (m) 
62.1 
6’b 3.26-3.09 (m) 
4.42 (dd, 
J=12.6, 4.2) 
4.40 (d, 
J=11.6) 
-OCOCH3 - - 
2.53 (s) 
2.49 (s) 
2.34 (s) 
2.32 (s) 
2.07 (s) 
2.06 (s) 
2.03 (s) 
1.80 (s) 
170.6, 170.5 
170.3,169.6 
168.5, 168.0 
167.7, 167.2 
21.4, 21.3 
21.1, 20.8 
20.7, 20.5 
20.4, 20.3  
2.44 (s) 
2.35 (s) 
2.34 (s) 
2.07 (s) 
2.05 (s) 
2.02 (s) 
1.78 (s) 
170.5, 170.2 
169.6, 169.4 
169.2, 168.0 
167.1, 
22.7, 21.3 
20.7, 20.7 
20.6, 20.5 
20.4 
1-OH 13.77 (s) - - - 13.25 (s) - 
3-OH 
6-OH 
7-OH 
10.57 (brs) - - - - - 
2’-OH 4.54 (s) - - - - - 
3’,4’-OH, 4.89 (s) - - - - - 
6’-OH 4.52 (s) - - - - - 
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APPENDIX II - 1H and 13C NMR data for compounds 8, 27, 11, and 12 (DMSO-d6). 
Compound 8 was elucidated in accordance with the literature. Values of chemical shift (δ) in parts 
per million (ppm). J values (Hz) are presented in parentheses. 
 
 
 
 
 
 
 
 
 
 
 
8 27 11 12 
1H 13C 1H 13C 1H 13C 1H 13C 
2 5.55-5.46 (m) 78.9 4.71-4.69 (m) 79.0 5.60-5.52 (m) 79.2 5.61-5.53 (m) 79.2 
3 
2.78-2.67 (2H, 
m) 
42.0 
3.38-3.13 
(2H, m)# 
-* 
2.82-2.73 (2H, 
m) 
45.4 
2.82-2.71 (2H, 
m) 
42.0 
4 - 197.3 - 197.3 - 197.2 - 197.2 
5 12.05 (OH, s) 162.9 - 157.0 12.05 (OH, s) 163.0 12.05 (OH, s) 163.3 
6 6.09-6.08 (m) 96.3 6.20-6.18 (brd) 97.1 6.13-6.08 (m) 96.4 6.16-6.08 (m) 96.3 
7 - 164.8 - 161.3 - 164.8 - 164.8 
8 6.11 (d, J=2.0) 95.2 6.04-5.95 (m) 96.0 6.20 (d, J=2.5) 95.2 6.16-6.08 (m) 95.2 
9 - 162.8 - 161.3 - 162.8 - 162.8 
10 - 103.3 - 103.3 - 103.4 - 103.3 
1’ - 128.7 - 129.5 - 128.5 - 128.5 
2’ 
7.33 (dd, 
J=8.7, 2.4,) 
128.6 7.58 (d, J=8.8) 129.8 
7.46 (dd, 
J=8.9, 2.4) 
128.4 
7.44 (dd, J=8.8, 
2.4) 
128.4 
3’ 6.80 (d, J=8.5) 115.3 7.17 (d, J=8.7) 120.1 7.02-6.97 (m) 115.1 6.93 (d, J=8.8) 115.0 
4’ 9.65 (OH, s) 157.9 - 155.6 - 157.9 - 157.9 
5’ 6.80 (d, J=8.5) 115.3 7.17 (d, J=8.7) 120.1 7.02-6.97 (m) 115.1 6.93 (d, J=8.8) 115.0 
6’ 
7.33 (dd, 
J=8.7, 2.4) 
128.5 7.58 (d, J=8.8) 129.8 
7.46 (dd, 
J=8.9, 2.4) 
128.2 
7.44 (dd, J=8.8, 
2.4) 
128.3 
1’’ 5.14-5.09 (m) 100.5 5.31-5.23 (m) 96.1 5.15-5.10 (m) 100.5 5.17-5.05 (m) 100.5 
2’’ 
3.48-3.29 (m)# 
77.1 
4.71-3.56 (m) 
66.9-
76.9 
3.54-3.30 (m)# 
77.1 
3.49-3.16 (m)# 
77.1 
3’’ 76.1 76.1 76.1 
4’’ 3.23-3.15 (m) 69.6 3.23-3.15 (m) 69.6 3.25-3.16 (m) 69.6 
5’’ 3.48-3.29 (m)# 76.9 3.54-3.30 (m)# 76.9 3.49-3.16 (m)# 76.9 
6’’a 3.70-3.65 (m) 
60.5 
3.74-3.64 (m) 
60.5 
3.74-3.64 (m) 
60.5 
6’’b 3.48-3.29 (m)# 3.54-3.30 (m)# 3.49-3.16 (m)# 
1’’’ 5.14-5.09 (m) 97.3 5.31-5.23 (m) 96.1 5.15-5.10 (m) 97.3 5.17-5.05 (m) 97.4 
2’’’ 3.70-3.65 (m) 70.5 
4.71-3.56 (m) 
66.9-
76.9 
3.74-3.64 (m) 70.5 
3.25-3.16 (m) 
70.5 
3’’’ 
3.23-3.15 (m) 
70.4 
3.23-3.15 (m) 
70.4 70.4 
4’’’ 71.8 72.1 71.8 71.8 
5’’’ 3.70-3.65 (m) 68.3 67.0 3.74-3.64 (m) 68.3 3.74-3.64 (m) 68.3 
OH 5.33 (d, J=4.8) - - - 
5.15-5.10 (m) 
- 
5.17-5.05 (m) 
- 
OH 5.15-5.09 (m) - - - - - 
OH 4.60-4.58 (m) - - - 
4.92-4.83 (m) 
- 4.51 (m) - 
OH 4.68 (d, J=4.3) - - - - 4.57 (d, J=4.4) - 
OH 4.50 (d, J=5.7) - - - - 4.43-4.38 (m) - 
OH 4.74 (d, J=4.6) - - - - 4.62 (d, J=3.5) - 
6’’’-CH3 1.15 (d, J=6.1) 18.1 1.27 (d, J=6.1) 18.1 1.15 (d, J=6.2) 18.1 1.16 (d, J=6.2) 18.1 
O-CH3 - - - - 3.71 (s) 51.9 - - 
-COCH3 - - - - - 169.2 - - 
O-CH2- - - - - 4.83 (s) 65.4 4.62 (s) 65.3 
-COOH - - - - - - 13.89 (s) 170.1 
*Under DMSO signal; #under water signal. 
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APPENDIX III - 1H and 13C NMR data for compounds 9 (DMSO-d6), 13 (CDCl3), and 14 (DMSO-d6). 
Compound 9 was elucidated in accordance with the literature.139 Values of chemical shift (δ) in parts 
per million (ppm). J values (Hz) are presented in parentheses. 
  
 
9 13 14 
1H 13C 1H 13C 1H 13C 
1a,b 
1.81-0.95 (m) 
35.0 
1.94-1.05 (m) 
34.9 1.82-0.97 (m) 35.1 
2a,b 30.3 30.5 1.82-0.97 (m) 28.7 
3 3.79 (d, J=2.4) 70.0 3.98-3.56 (m) 71.8 3.79 (s) 70.0 
3-OH 4.48 (d, J=2.6) - 4.00 (t, J=2.8) - 4.49 (s) - 
4 
1.81-0.95 (m) 
35.7 
1.94-1.05 (m) 
36.0 
1.82-0.97 (m) 
35.7 
5 41.6 42.1 42.3 
6 27.2 27.4 27.2 
7 26.1 26.1 26.1 
8 36.3 36.4 36.3 
9 32.9 33.7 32.9 
10 33.8 34.1 33.8 
11 28.6 28.0 28.6 
12 4.21 (d, J=3.9) 71.0 3.77-3.73 (m) 73.1 4.21 (brd) 71.0 
13 1.81-0.95 (m) 46.0 1.94-1.05 (m) 46.6 1.82-0.97 (m) 46.0 
14 - 47.5 - 48.2 - 47.5 
15 - 23.5 - 23.6 - 23.5 
16 - 27.0 - 27.1 - 27.0 
17 - 46.2 - 47.1 - 46.2 
18-CH3 0.59 (s) 12.5 0.70 (s) 12.7 0.59 (s) 12.5 
19-CH3 0.84 (s) 23.1 0.91 (s) 23.2 0.84 (s) 23.1 
20 1.81-0.95 (m) 35.2 1.94-1.05 (m) 35.2 1.82-0.97 (m) 35.1 
21-CH3 0.91 (d, J=6.2) 16.9 1.01 (d, J=6.1) 17.3 0.92 (d, J=6.2) 17.1 
22 
1.81-0.95 (m) 
30.9 1.94-1.05 (m) 30.5 1.82-0.97 (m) 32.9 
23a 
30.8 2.67-2.55 (m) 30.5 
2.13-2.04 (m) 
32.5 
23b 2.12-2.09 (m) 2.00-1.90 (m) 
24 - 175.0 - 169.1 - 172.7 
-CH2-CH2- 
(NHS) 
- - 2.87-2.82 (m) 25.6 - - 
C=O (NHS) - - - 169.2 - - 
-NH- - - - - 7.72 (t, J=10.9) - 
-NH2 - - - - 1.82-0.97 (m) - 
CH2-CH2 
(EDA) 
- - - - 
3.01 (q, J=12.2, 
6.3) 
41.6 
41.4 
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APPENDIX IV - 1H and 13C NMR data for compounds 10, 15, and 16 (DMSO-d6). 
 Values of chemical shift (δ) in parts per million (ppm). J values (Hz) are presented in parentheses. 
 
  
 
10 15 16 
1H 13C 1H 13C 1H 13C 
2 5.70-5.61 (m) 77.0 5.54-5.50 (m) 77.4 5.35-5.20 (m) 78.8 
3 
2.89-2.87 (m) 
2.83-2.81 (m) 
41.6 2.89-2.71 (m) 46.4 2.72-2.61 (m) 45.6 
5 12.03 (OH, s) 163.0 12.06 (OH, s) 163.0 - 163.4 
6,8 6.15-6.09 (m) 
97.0 
95.0 
6.21-6.10 (m) 96.8 6.19-5.98 (m) 96.0 
7 - 162.8 - 164.8 - 164.7 
2’,6’ 7.56 (d, J=8.1) 128.0 
7.87-7.79 (m) 
7.49-7.45 (brd) 
128.9 
7.90 (brd) 
7.49 (brd) 
128.0 
3’,5’ 7.17 (d, J=8.5) 122.0 7.03-6.99 (brd) 115.6 7.03 (m) 114.8 
1’’ 5.09 (brd) 100.7 
5.18-5.10 (m) 
100.9 
5.35-5.20 (m) 
100.8 
1’’’ 5.20-5.16 (m) 97.0 97.4 97.3 
neohesperidoside 
3.73-3.67 (m) 
3.51-3.28 (m) 
3.23-3.16 (m) 
71.1-
68.0 
3.77-3.69 (m) 
3.55-3.35 (m)* 
76.6-
60.9 
4.75-4.68 (m) 
4.53-4.42 (m) 
4.01-3.70 (m) 
76.1-
71.5 
6’’’-CH3 1.17 (d, J=6.2) 18.1 1.75-1.14 (m) 18.4 1.90-1.16 (m) 18.0 
OH 
5.42 (d, J=5.2) 
5.47 (d, J=4.6) 
4.75 (dd, J=4.2, 
2.3) 
4.69 (d, J=4.3) 
- 
4.77-4.53 (m) 
5.36-5.32 (m) 
- - - 
-OCH2- - - 4.77-4.53 (m) 67.2 4.53-4.42 (m) 67.0 
3 (D) 
3.81 (d, J=2.9, 
OH) 
3.73-3.67 (m) 
70.0 
4.77-4.53 (OH, 
m) 
3.77-3.69 (m) 
70.5 4.01-3.70 (m) 76.1 
12 (D) 4.26 (d, J=2.9) 71.1 4.19 (brd) 71.6 4.53-4.42 (m) 78.0 
steroid 1.82-1.16 (m) 
47.5-
23.5 
1.75-1.14 (m) 
47.8-
23.9 
1.90-1.16 (m) 
48.2-
23.6 
18-CH3 0.63 (s) 
12.4 
12.5 
0.59 (s) 12.8 0.62 (s) 12.3 
19-CH3 0.85 (s) 23.1 0.84 (s) 23.5 0.85 (s) 23.2 
21-CH3 0.99 (d, J=5.7) 
16.7 
17.0 
0.91 (d, J=6.0) 17.4 0.94 (d, J=6.4) 17.4 
23 (D) 2.28-2.18 (m) 30.6 2.07-1.91 (m) 31.6 2.13-2.09 (m) 31.6 
N-CH2CH2-N - - 3.18-3.15 (m) 38.5 3.16-3.15 (m) 
38.2 
38.4 
NH-amide - - 
8.17 (s) 
7.87-7.79 (m) 
174.3 
168.6 
8.24 (s) 
7.90 (brd) 
173.1 
167.8 
*under water signal 
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APPENDIX V - 1H and 13C NMR data for compounds 19, 20, 21, and 22 (DMSO-d6). 
For all the compounds sugar protons were assigned using the 1H and 13C data of glucosamine. 140 
Values of chemical shift (δ) in part per million (ppm). J values (Hz) are presented in parentheses. 
 
19 20 21 22 
1H 13C 1H 13C 1H 13C 1H 13C 
1/8 
8.09 
(d, J=8.9) 
127.5 
8.10 
(d, J=9.0) 
127.5 
8.08 
(d, J=8.9) 
127.6 
8.07 
(d, J=8.8) 
127.5 
2/7 
7.10 
(dd, J=9.0, 
2.3) 
113.8 
7.12 
(dd, J=8.9, 
2.1) 
113.8 
7.11 
(d, J=8.9) 
113.9 
7.13 
(d, J=7.5) 
113.9 
3/6 - 163.3 - 163.3 - 163.3 - 163.4 
4/5 
7.34 
(d, J=2.3) 
101.5 
7.35 (d, 
J=2.1) 
101.5 7.33 (brd) 101.5 7.35 (brd) 101.5 
4a/10a - 157.4 - 157.4 - 157.5 - 157.5 
9 - 174.1 - 174.1 - 174.0 - 174.2 
8a/9a - 115.0 - 115.2 - 115.2 - 115.2 
1’/1’’ 
4.70 
(d, J=8.5) 
99.8 
4.33 
(d, J=8.4) 
100.7 4.61-4.55 (m) 101.5 4.15-4.08 (m) 100.5 
2’/2’’ 
3.76 
(q, J=8.9) 
52.8 
3.49-3.40 
(m)* 
55.1 
3.11-3.04 (m) 
49.8 
3.84-3.30 (m)* 
53.0 
3’/3’’ 
4.85 
(t, J=9.7) 
68.4 3.18-3.04 (m) 70.5 70.9 70.5 
4’/4’’ 4.21-4.02 (m) 70.7 3.29-3.25 (m) 74.1 76.5 74.5 
5’/5’’ 
5.07 
(t, J= 10.0) 
72.5 3.18-3.04 (m) 77.1 77.2 76.9 
6’/6’’a,b 4.21-4.02 (m) 61.7 3.73-3.68 (m) 61.0 3.71-3.67 (m) 61.1 61.9 
-OH - - 5.08 (brd) - 5.04 (brd) - - - 
-OH - - 5.01 (brd) - 4.96 (brd) - - - 
-OH - - 4.60-4.57 (m) - 4.62-4.55 (m) - - - 
O-CH2-
triazole 
5.33 (s) 61.9 5.33 (s) 61.9 5.35 (s) 61.9 5.33 (s) 61.9 
CH=C-
triazole 
8.15 (s) 
125.4 
141.5 
8.18 (s) 
125.5 
141.6 
8.37 (s) 
125.8 
141.7 
8.27 (s) 
125.5 
141.7 
N-CH2CH2-O 
4.60-4.57 (m) 
4.21-4.02 (m) 
67.2 
49.4 
4.60-4.57 (m) 
4.12-4.08 (m) 
3.87-3.81 (m) 
66.5 
49.6 
4.62-4.55 (m) 
67.3 
49.8 
4.15-4.08 (m) 
4.63-4.60 (m) 
66.1 
49.5 
-OCOCH3 
2.02 (s) 
1.97 (s) 
1.91 (s) 
170.1 
169.7 
169.4 
20.5 
20.4 
20.3 
- - - - - - 
-NHCOCH3 1.71 (s) 
169.1 
22.6 
 
169.3 
23.0 
- - - - 
-NHCOCH3 
7.92 
(d, J=9.1) 
- 
7.70 
(d, J=8.9) 
- - - - - 
-NH2 - - - - 1.44 (s) - 1.73 (s) - 
*under water 
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APPENDIX VI - 1H and 13C NMR data for compounds 23 (DMSO-d6) and 24 (CDCl3). 
Data for compound 23 is in accordance with the literature.141 Values of chemical shift (δ) in parts per 
million (ppm). J values (Hz) are presented in parentheses. 
 
 
 
23 24 
1H 13C 1H 13C 
2 - 164.5  159.8 
3 6.79 (s) 105.7 6.51 (s) 109.0 
4 - 182.3  176.2 
5 12.95 (s, OH) 161.1 - 159.8 
6 6.44 (d, J=1.8) 99.9 6.65 (d, J=2.4) 98.1 
7 - 163.2 - 161.5 
8 6.75 (d, J=1.8) 95.1 6.96 (d, J=2.4) 97.8 
9 - 157.2 - 150.7 
10 - 104.0 - 102.4 
1’ - 123.0 - 123.9 
2’ 7.41 (d, J=2.0) 112.9 7.56 (d, J=2.3) 112.5 
3’ 9.73 (brs, OH) 146.9 - 140.1 
4’ - 151.6 - 154.0 
4’-OCH3 3.84 (s) 56.0 3.91 (s) 56.2 
5’ 7.10 (d, J=9.0) 113.3 7.08 (d, J=8.8) 112.8 
6’ 7.54 (dd, J=9.0, 2.0) 119.3 7.72 (dd, J=9.0, 2.3) 121.0 
1’’ 4.51 (d, J=7.0) 100.1 
5.98-5.37 (m) 
97.8 
2’’ 
3.75-3.13 (m) 
73.3 70.9 
3’’ 76.4 72.4 
4’’ 70.9 70.8 
5’’ 75.8 3.85-3.80 (m) 73.5 
6’’a, b 66.2 
3.85-3.80 (m) 
3.70-3.65 (m) 
68.6 
1’’’ 5.03 (d, J=7.0) 100.7 4.72 (s) 98.1 
2’’’ 
3.75-3.13 (m) 
70.5 5.05-4.97 (m) 69.3 
3’’’ 69.8 
5.98-5.37 (m) 
68.9 
4’’’ 72.3 70.8 
5’’’ 68.6 4.01-3.95 (m) 66.7 
6’’’-CH3 1.04 (d, J=6.1) 18.0 1.15 (d, J=6.2) 17.3 
OH 5.55 (d, J=4.4) - - - 
OH 5.30 (d, J=5.4) - - - 
OH 5.25 (d, J=4.3) - - - 
OH 4.80 (m) - - - 
OH 4.69 (m) - - - 
OH 4.52 (m) - - - 
-COCH3 - - 
2.43 (s) 
2.36 (s) 
2.17 (s) 
2.09-2.02 (m) 
1.92 (s) 
170.2, 170.0 
169.9, 169.8 
169.7, 169.4 
169.3, 168.8 
31.0, 29.7 
21.1, 20.8 
20.8, 20.7, 
20.6 
Potential Orally-Active Heparin-Like Compounds: Synthesis and Anticoagulant Activity 
 
121 
 
APPENDIX VII - 1H and 13C NMR data for compounds 25 (DMSO-d6) and 26 (CDCl3). 
Compound 25 was elucidated in accordance with the literature.74, 129 Values of chemical shift (δ) in 
parts per million (ppm). J values (Hz) are presented in parentheses. 
 
 
 
 
25 26 
1H 13C 1H 13C 
2 - 156.5 - 156.6 
3 - 133.3 - 136.9 
4 - 177.4 - 171.9 
5 12.60 (s, OH) 161.3 - 150.2 
6 6.21 (d, J=1.9) 98.8 6.83 (d, J=2.2) 113.4 
7 10.77 (s, OH) 164.1 - 153.9 
8 6.40 (d, J=1.9) 100.8 7.31 (d, J=2.2) 109.1 
9 - 156.7 - 154.7 
10 - 101.2 - 115.1 
1’ - 121.2 - 128.6 
2’ 7.54 (m) 115.3 7.91 (d, J=2.1) 124.7 
3’ 9.60 (OH, s) 144.8 - 141.8 
4’ 9.17 (OH, s) 149.5 - 144.1 
5’ 6.85 (d, J=9.0) 116.3 7.34 (d, J=8.6) 123.5 
6’ 7.56 (m) 121.7 7.96 (dd, J=8.6, 2.2) 127.2 
1’’ 5.37-5.34 (m) 93.7 5.43 (d, J=7.8) 99.6 
2’’ 3.34-3.23 (m) 76.5 5.17 (dd, J=9.8, 7.8) 71.4 
OH 5.27 (m) - - - 
3’’ 3.34-3.23 (m) 144.8 5.28 (t, J=9.6) 72.5 
OH 5.07 (m) - - - 
4’’ 3.12-3.06 (m) 148.5 4.95 (t, J=9.7) 69.5 
OH 5.07 (m) - - - 
5’’ 3.34-3.23 (m) 71.9 3.60-3.54 (m) 72.8 
6’’a 3.72 (d, J=10.1) 
67.1 
3.53 (dd, J=12.5, 
3.1) 
66.9 
6’’b 3.34-3.23 (m) 
3.26 (dd, J=11.3, 
5.9) 
1’’’ 4.40 (m) 104.0 4.52 (brs) 97.7 
2’’’ 
3.34-3.23 (m) 
70.6 
5.09-5.06 (m) 
69.3 
3’’’ 70.4 69.0 
4’’’ 3.12-3.06 (m) 68.3 4.95 (t, J=9.7) 70.9 
5’’’ 3.34-3.23 (m) 67.1 3.67-3.62 (m) 66.3 
6’’’-CH3 1.00 (d, J=6.1) 17.8 1.06 (d, J=6.2) 17.2 
COCH3 - - 
2.44 (s), 2.35 (s) 
2.34 (s), 2.30 (s) 
2.14 (s), 2.09 (s) 
2.03 (s), 1.96 (s) 
1.94 (s), 1.60 (s) 
170.2. 169.9 
169.9, 169.8 
169.8, 169.6 
169.3, 168.1 
167.9, 167.8 
21.2, 21.1 
20.9, 20.9 
20.7, 20.7 
20.7, 20.6 
